4-hydroxybutanoic acid (GHB) and any salt thereofC |
|
I |
NOV / 20 |
Abacavir or its saltsPDL |
|
I |
DEC / 13 |
AbataceptPDL |
|
I |
DEC / 13 |
AbciximabPDL |
|
I |
DEC / 13 |
Abemaciclib or its saltsPDL |
|
I |
JUL / 19 |
Abiraterone or its derivativesPDL |
including but not limited to abiraterone acetate
|
I |
DEC / 13 |
Acalabrutinib or its saltsPDL |
|
I |
OCT / 19 |
Acamprosate or its saltsPDL |
|
I |
DEC / 13 |
Acarbose or its derivativesPDL |
|
I |
DEC / 13 |
Acebutolol or its saltsPDL |
|
I |
DEC / 13 |
Acepromazine or its saltsPDL |
for human use
|
I |
DEC / 13 |
AcetaminophenPDL |
when recommended for administration by intravenous injection
|
I |
DEC / 13 |
Acetaminophen and ibuprofen |
When sold in oral, fixed-dose combinations, in package sizes containing 20,000 mg or less of acetaminophen and 6,000 mg or less of ibuprofen*
*Note that this listing does not apply to products containing ibuprofen that would meet the criteria to be included on the Prescription Drug list, as these would require a prescription
|
III |
JUL / 20 |
Acetaminophen and ibuprofen |
When sold in oral, fixed-dose combinations, in package sizes containing either more than 20,000 mg of acetaminophen or more than 6,000 mg of ibuprofen*
*Note that this listing does not apply to products containing ibuprofen that would meet the criteria to be included on the Prescription Drug list, as these would require a prescription
|
II |
JUL / 20 |
Acetaminophen in sustained release formulations |
up to and including 650 mg per unit, in package sizes containing no more than 50 units
|
U |
JAN / 03 |
Acetaminophen in sustained release formulations. |
in strengths of greater than 650 mg per unit or in package sizes of more than 50 units
|
III |
JAN / 03 |
Acetaminophen. |
in immediate release tablets, capsules, suppositories or liquid |
U |
SEP / 99 |
AcetanilidePDL |
for human use
|
I |
DEC / 13 |
Acetarsol |
|
II |
SEP / 98 |
AcetazolamidePDL |
|
I |
DEC / 13 |
AcetohexamidePDL |
|
I |
DEC / 13 |
AcetylcarbromalPDL |
|
I |
DEC / 13 |
Acetylcholine ChloridePDL |
|
I |
DEC / 13 |
Acetylcysteine |
|
II |
SEP / 98 |
Acetylsalicylic acid and its salts |
oral preparations containing 80 mg or less per dosage unit and intended for pediatric use or rectal preparations containing 150 mg or less per dosage unit, in package sizes containing no more than 1.92 g of acetylsalicylic acid. |
II |
FEB / 02 |
Acetylsalicylic acid and its salts. |
in products for oral use in strengths of 325mg and 500mg per dosage unit |
U |
OCT / 00 |
Acetylsalicylic acid and its salts.. |
in products intended for oral adult use in strengths of 81 mg per dosage unit and 650 mg or greater per dosage unit, and in rectal preparations containing more than 150 mg per dosage unit |
III |
OCT / 00 |
Acitretin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Aclidinium or its saltsPDL |
|
I |
DEC / 13 |
Aconiazide or its saltsPDL |
|
I |
DEC / 13 |
Acyclovir or its saltsPDL |
|
I |
DEC / 13 |
AdalimumabPDL |
|
I |
DEC / 13 |
Adapalene or its salts or derivativesPDL |
|
I |
DEC / 13 |
Adefovir or its salts or derivativesPDL |
including but not limited to adefovir dipivoxil
|
I |
DEC / 13 |
Adenosine or its saltsPDL |
when sold or recommended for administration by intravenous injection
|
I |
DEC / 13 |
Adiphene and its salts |
for parenteral use |
II |
SEP / 98 |
Adrenocortical hormones or their salts or derivativesPDL |
for human use including but not limited to: Betamethasone valerate, betamethasone sodium, betamethasone phosphate, betamethasone dipropionate, budesonide, ciclesonide, clobetasone, cortisone, dexamethasone sodium, dexamethasone phosphate, dexamethasone acetate, difluprednate, fludrocortisone acetate, flunisolide, fluticasone propionate, fluticasone furoate, hydrocortisone acetate, hydrocortisone aceponate, hydrocortisone sodium, methylprednisolone acetate, methylprednisolone, methylprednisolone succinate, methylprednisolone sodium, mometasone furoate, prednisolone acetate, prednisolone sodium, prednisolone phosphate, prednisone, triamcinolone acetonide, triamcinolone hexacetonide except: (a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 1.0% or less hydrocortisone in preparations for topical use on the skin; or (b) hydrocortisone or hydrocortisone acetate, when sold in combination with any other nonprescription medicinal ingredient that provides 1.0% or less hydrocortisone in preparations for topical use on the skin; or (c) clobetasone butyrate when sold in a concentration of 0.05% in cream preparations for topical use on the skin; or (d) triamcinolone acetonide in a nasal spray that delivers 55 microgram (mcg)/spray for those 12 years of age and older; or, (e) mometasone furoate for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 12 years of age and older; or (f) fluticasone propionate for the treatment of allergic rhinitis in a nasal spray that delivers 50 microgram/spray for those 18 years of age and older.
|
I |
AUG / 16 |
Afatinib or its saltsPDL |
|
I |
DEC / 13 |
AfliberceptPDL |
|
I |
DEC / 13 |
AfoxolanerPDL |
|
I |
AUG / 14 |
Agalsidase AlfaPDL |
|
I |
APR / 07 |
Agalsidase BetaPDL |
|
I |
DEC / 14 |
AlbiglutidePDL |
|
I |
AUG / 15 |
AldesleukinPDL |
|
I |
DEC / 13 |
Alectinib or its saltsPDL |
|
I |
NOV / 16 |
AlefaceptPDL |
|
I |
DEC / 13 |
AlemtuzumabPDL |
|
I |
DEC / 13 |
Alendronic acid or its saltsPDL |
|
I |
DEC / 13 |
AlfacalcidolPDL |
|
I |
DEC / 13 |
Alfuzosin or its saltsPDL |
|
I |
DEC / 13 |
Alglucosidase alfaPDL |
|
I |
DEC / 13 |
AlirocumabPDL |
|
I |
AUG / 16 |
Aliskiren or its saltsPDL |
|
I |
DEC / 13 |
Alitretinoin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Alkyl nitritesPDL |
|
I |
DEC / 13 |
Allergy serums and extracts |
|
I |
SEP / 99 |
Allethrins |
|
II |
SEP / 98 |
AllopurinolPDL |
|
I |
DEC / 13 |
AllylisopropylacetylureaPDL |
|
I |
DEC / 13 |
Almotriptan or its saltsPDL |
|
I |
DEC / 13 |
Alogliptin or its salts or its derivativesPDL |
|
I |
DEC / 13 |
Alpelisib or its saltsPDL |
|
I |
JUL / 20 |
Alpha-chloralosePDL |
|
I |
DEC / 13 |
Alpha-hydroxy acidsPDL |
including but not limited to citric acid, glycolic acid, lactic acid, malic acid, mandelic acid, ammonium glycolate, glycolic acid + ammonium glycolate, alpha-hydroxyethanoic acid + ammonium alpha-hydroxyethanoate, alpha-hydroxyoctanoic acid, alpha-hydroxycaprylic acid, hydroxycaprylic acid, mixed fruit acid, triple fruit acid, tri-alpha hydroxy fruit acids, alpha hydroxy and botanical complex, l-alpha hydroxy acid, glycomer in cross-linked fatty acids alpha nutrium, when sold in topical formulations containing alpha hydroxy acids alone or in combination at concentrations of greater than 30% and/or with a pH lower than 3.0, except when sold to be applied to warts, corns or calluses
|
I |
DEC / 14 |
Alphadolone or its saltsPDL |
|
I |
DEC / 13 |
AlphaxalonePDL |
including but not limited to alfaxalone, alphaxolone
|
I |
DEC / 13 |
Alteplase or its salts or derivativesPDL |
including but not limited to tenecteplase
|
I |
DEC / 13 |
AltrenogestPDL |
|
I |
DEC / 13 |
AltretaminePDL |
|
I |
DEC / 13 |
Alverine and its salts |
for parenteral use |
I |
SEP / 98 |
Amantadine or its saltsPDL |
|
I |
DEC / 13 |
Ambenonium ChloridePDL |
|
I |
DEC / 13 |
AmbrisentanPDL |
|
I |
DEC / 13 |
Amidones, their intermediates, salts, derivatives and salts of intermediates and derivativesN |
Including: Dimethylaminodiphenylbutanonitrile; Dipipanone; Isomethadone; Methadone; Normethadone; Norpipanone; Phenadoxone
|
I |
JUN / 02 |
Amifampridine or its salts or derivatives PDL |
|
I |
SEP / 20 |
Amifostine or its saltsPDL |
|
I |
DEC / 13 |
Amikacin or its salts or derivativesPDL |
PDL, including but not limited to amikacin sulfate
|
I |
DEC / 13 |
Amiloride or its saltsPDL |
|
I |
DEC / 13 |
Amineptine and any salt thereofC |
|
I |
NOV / 20 |
Amino Acid solutions |
for parenteral use |
I |
SEP / 99 |
Amino-pteroyl aspartic acid or its saltsPDL |
|
I |
DEC / 13 |
Aminocaproic acidPDL |
|
I |
DEC / 13 |
AminoglutethimidePDL |
|
I |
DEC / 13 |
Aminolevulinic acid or its salts or derivativesPDL |
|
I |
DEC / 13 |
AminophyllinePDL |
|
I |
DEC / 13 |
Aminopromazine [proquamezine] and its salts |
|
I |
SEP / 98 |
Aminopterin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Aminopyrine or its derivativesPDL |
for human use
|
I |
DEC / 13 |
Aminorex, its salts, derivatives, isomers and analogues and salts of derivatives, isomers and analoguesC |
Including 4-Methylaminorex and 4,4'-Dimethylaminorex.
|
I |
DEC / 17 |
Aminosalicylic Acid or its saltsPDL |
|
I |
DEC / 13 |
Aminosalicylic acidPDL |
including but not limited to mesalazine
|
I |
DEC / 13 |
Amiodarone or its salts or derivativesPDL |
including but not limited to dronedarone
|
I |
DEC / 13 |
AmitrazPDL |
|
I |
DEC / 13 |
Amitriptyline or its saltsPDL |
|
I |
DEC / 13 |
Amlexanox or its salts or derivativesPDL |
|
I |
DEC / 13 |
Amlodipine or its saltsPDL |
|
I |
DEC / 13 |
Ammonium bromidePDL |
|
I |
DEC / 13 |
AmoxapinePDL |
|
I |
DEC / 13 |
Amphetamines, their salts, derivatives, isomers and analogues and salts of derivatives, isomers and analoguesC |
Excluding those substances set out in item 1 of Part I of the schedule to Part J (of the Food and Drug Regulations) but including: amphetamine; methamphetamine; Benzphetamine
|
I |
JUN / 02 |
Amphotericin B or its salts or derivativesPDL |
|
I |
DEC / 13 |
Amprenavir or its salts or derivativesPDL |
including but not limited to fosamprenavir
|
I |
DEC / 13 |
Amprolium or its saltsPDL |
for human use
|
I |
DEC / 13 |
Ampromides, their salts, derivatives and salts of derivativesN |
Including: Diampromide, Phenampromide, Propiram
|
I |
JUN / 02 |
Amrinone or its saltsPDL |
|
I |
DEC / 13 |
Amsacrine or its saltsPDL |
|
I |
DEC / 13 |
Amylocaine and its salts |
in preparations for topical use on mucous membranes except lozenges |
III |
SEP / 98 |
Amylocaine and its salts |
for ophthalmic or parenteral use |
II |
SEP / 98 |
Anabolic steroids and their derivativesC |
Including: Androisoxazole; Androstanolone; Androstenediol; Bolandiol; Bolasterone; Bolazine; Boldenone; Bolenol; Calusterone; Clostebol; Drostanolone; Enestebol; Epitiostanol; Ethylestrenol; 4-Hydroxy-19-nor testosterone; Fluoxymesterone; Formebolone; Furazabol; Mebolazine; Mesabolone; Mesterolone; Metandienone; Metenolone; Methandriol; Methyltestosterone; Metribolone; Mibolerone; Nandrolone; Norboletone; Norclostebol; Norethandrolone; Oxabolone; Oxandrolone; Oxymesterone; Oxymetholone; Prasterone; Quinbolone; Stanozolol; Stenbolone; Testosterone; Tibolone; Tiomesterone; Trenbolone
|
I |
JUN / 02 |
Anagrelide or its saltsPDL |
|
I |
DEC / 13 |
Anakinra or its salts or derivativesPDL |
|
I |
DEC / 13 |
AnastrozolePDL |
|
I |
DEC / 13 |
AncestimPDL |
|
I |
DEC / 13 |
Anetholtrithione |
|
III |
SEP / 98 |
AnidulafunginPDL |
|
I |
DEC / 13 |
Anisotropine and its salts |
|
II |
SEP / 98 |
Antazoline and its salts |
|
III |
SEP / 98 |
Anthralin |
|
II |
SEP / 98 |
Anti-thymocyte globulinPDL |
|
I |
DEC / 13 |
Antihemophilic factor, human |
|
II |
SEP / 98 |
AntipyrinePDL |
for human use, except preparations for topical use
|
I |
DEC / 13 |
Antipyrine. |
except otic preparations
|
II |
SEP / 98 |
Antipyrine.. |
for otic use
|
III |
SEP / 98 |
Apalutamide or its saltsPDL |
|
I |
JUL / 18 |
Apixaban or its derivativesPDL |
|
I |
DEC / 13 |
Apomorphine or its saltsPDL |
|
I |
FEB / 17 |
Apraclonidine or its saltsPDL |
|
I |
DEC / 13 |
Apramycin or its saltsPDL |
|
I |
DEC / 18 |
ApremilastPDL |
|
I |
DEC / 14 |
Aprepitant or its derivativesPDL |
including but not limited to fosaprepitant
|
I |
DEC / 13 |
AprotininPDL |
|
I |
DEC / 13 |
Argatroban or its salts or derivativesPDL |
|
I |
DEC / 13 |
Arginine and its salts |
|
II |
SEP / 98 |
Aripiprazole or its saltsPDL |
|
I |
DEC / 13 |
Arsenic trioxidePDL |
|
I |
DEC / 13 |
Artemisia, its preparations, extracts and compounds |
except in trace amounts in homeopathic preparations |
II |
SEP / 98 |
Asenapine or its salts or derivativesPDL |
including but not limited to asenapine maleate
|
I |
DEC / 13 |
Asfotase alfaPDL |
|
I |
OCT / 15 |
AsparaginasePDL |
when sold for administration by injection
|
I |
DEC / 13 |
Astemizole or its saltsPDL |
|
I |
DEC / 13 |
AsunaprevirPDL |
|
I |
AUG / 16 |
Atazanavir or its saltsPDL |
|
I |
DEC / 13 |
Atenolol or its saltsPDL |
|
I |
DEC / 13 |
AtezolizumabPDL |
|
I |
MAY / 17 |
Atipamezole or its saltsPDL |
|
I |
DEC / 13 |
Atomoxetine or its saltsPDL |
|
I |
DEC / 13 |
Atorvastatin or its saltsPDL |
|
I |
DEC / 13 |
AtovaquonePDL |
|
I |
DEC / 13 |
Atracurium besilatePDL |
|
I |
DEC / 13 |
Atropine or its saltsPDL |
including but not limited to atropine sulphate, in ophthalmic or parenteral preparations
|
I |
DEC / 13 |
AvelumabPDL |
|
I |
MAR / 18 |
Avermectin or its derivativesPDL |
including but not limited to ivermectin, selamectin, doramectin for human use
|
I |
DEC / 13 |
Avermectin or its derivatives.PDL |
For veterinary use - including but not limited to Ivermectin, selamectin, doramectin. Ivermectin when when recommended for intramuscular injection for horses or for oral administration to dogs and cats, except doramectin.
|
I |
DEC / 13 |
Avilamycin or its salts or derivativesPDL |
|
I |
MAR / 14 |
Axicabtagene ciloleucelPDL |
|
I |
MAR / 19 |
Axitinib or its salts or derivativesPDL |
|
I |
DEC / 13 |
Azacitidine or its salts or derivativesPDL |
|
I |
DEC / 13 |
Azacyclonol or its saltsPDL |
|
I |
DEC / 13 |
AzaribinePDL |
|
I |
DEC / 13 |
Azathioprine or its saltsPDL |
|
I |
DEC / 13 |
Azatidine or its saltsPDL |
including but not limited to azatadine
|
I |
DEC / 13 |
Azelaic acidPDL |
|
I |
DEC / 13 |
Azelastine or its saltsPDL |
|
I |
DEC / 14 |
Azilsartan medoxomil or its salts or derivativesPDL |
|
I |
DEC / 13 |
Aztreonam or its saltsPDL |
|
I |
DEC / 13 |
Bacillus Calmette-Guérin (BCG) |
Including but not limited to Bacillus Calmette-Guérin (BCG), Strain TICE, when sold or recommended as an antineoplastic agent.
|
I |
NOV / 19 |
Bacillus Calmette-Guérin (BCG)PDL |
|
I |
FEB / 02 |
Bacitracin or its salts or derivativesPDL |
For veterinary use
|
I |
DEC / 18 |
Bacitracin or its salts or derivatives . |
For human use: for parenteral use
|
I |
SEP / 98 |
Bacitracin or its salts or derivatives .. |
For human use: for topical use
|
U |
SEP / 98 |
Bacitracin or its salts or derivatives … |
For human use: for ophthalmic use
|
III |
JUN / 06 |
Baclofen or its saltsPDL |
|
I |
DEC / 13 |
Baloxavir marboxilPDL |
|
I |
JUL / 20 |
Bambuterol or its saltsPDL |
|
I |
DEC / 13 |
BamlanivimabPDL |
|
I |
NOV / 20 |
Barbiturates, their salts and derivativesC |
Excluding the substances set out in items 6 and 7 of Part I of this schedule (Schedule G of the Food and Drug Regulations), as well as barbituric acid and its salts and 1,3-dimethylbarbituric acid and its salts, but including: Allobarbital; Alphenal; Amobarbital; Aprobarbital; Barbital; Butabarbital; Butalbital; Butallylonal; Butethal; Cyclobarbital; Cyclopal; Heptabarbital; Hexethal; Hexobarbital; Mephobarbital; Methabarbital; Methylphenobarbital; Propallylonal;
Phenobarbital; Probarbital; Phenylmethylbarbituric Acid; Sigmodal; Talbutal; Vinbarbital; Vinylbital
|
I |
JUN / 02 |
Baricitinib or its saltsPDL |
|
I |
OCT / 18 |
BasiliximabPDL |
|
I |
DEC / 13 |
Bazedoxifene or its saltsPDL |
|
I |
DEC / 14 |
BecaplerminPDL |
|
I |
DEC / 13 |
BelimumabPDL |
|
I |
DEC / 13 |
Belladonna alkaloids, and their salts and derivatives |
except in preparations for topical use or in trace amounts in homeopathic preparations |
II |
SEP / 98 |
BemegridePDL |
|
I |
DEC / 13 |
Benactyzine or its salts |
|
I |
DEC / 13 |
Benazepril or its salts or derivatives |
including but not limited to benazepril hydrochloride
|
I |
DEC / 13 |
Bendamustine or its salts or derivatives |
including but not limited to bendamustine hydrochloride
|
I |
DEC / 13 |
Bendazac or its salts |
|
I |
DEC / 13 |
Benoxaprofen or its salts |
|
I |
DEC / 13 |
Benoxinate hydrochloride |
oxybuprocaine for ophthalmic or parenteral use |
II |
SEP / 98 |
Benralizumab |
|
I |
MAY / 18 |
Benserazide or its salts |
|
I |
DEC / 13 |
Bentiromide |
|
II |
SEP / 98 |
Benzalkonium and its salts |
liquid preparations in concentrations of more than 2% |
II |
SEP / 98 |
Benzazocines, their salts, derivatives and salts of derivativesN |
Including: Phenazocine, Metazocine, Pentazocine; but not including: Cyclazocine and its salts
|
I |
JUN / 02 |
Benzethonium chloride |
liquid preparations in concentrations of more than 1% |
II |
SEP / 98 |
Benzimidazoles, their salts, derivatives and salts of derivativesN |
Including: Clonitazene, Etonitazene
|
I |
JUN / 02 |
Benzocaine and its salts |
for parenteral or ophthalmic use |
II |
SEP / 98 |
Benzodiazepines, their salts and derivativesTS |
Including: Alprazolam, Bromazepam, Brotizolam, Camazepam, Chlordiazepoxide, Clobazam, Clonazepam, Clorazepate, Cloxazolam, Delorazepam, Diazepam, Estazolam, Ethyl Loflazepate, Fludiazepam, Flurazepam, Halazepam, Haloxazolam, Ketazolam, Loprazolam, Lorazepam, Lormetazepam, Medazepam, Midazolam, Nimetazepam, Nitrazepam, Nordazepam, Oxazepam, Oxazolam, Pinazepam, Prazepam, Quazepam, Temazepam, Tetrazepam, Triazolam; but not including: Clozapine and any salt thereof, Flunitrazepam and any salts or derivatives thereof, Olanzapine and its salts, Clozapine N-oxide and its salts
|
I |
SEP / 98 |
Benzonatate |
|
III |
SEP / 98 |
Benzoyl peroxide |
in concentrations greater than 5% or when sold in combination with another medicinal ingredient
|
I |
DEC / 13 |
Benzoyl peroxide. |
preparations of 5% or less as a single ingredient |
U |
MAY / 08 |
Benztropine or its salts |
including but not limited to benzatropine
|
I |
DEC / 13 |
Benzydamine or its salts |
|
I |
DEC / 13 |
Benzyl benzoate |
|
II |
SEP / 98 |
Bepotastine or its salts or derivatives |
|
I |
NOV / 16 |
Beractant |
|
I |
DEC / 13 |
Besifloxacin or its salts |
|
I |
DEC / 13 |
Betahistine or its salts |
|
I |
DEC / 13 |
Betaine or its salts |
for human use, when sold or recommended for the treatment of homocystinuria
|
I |
DEC / 13 |
Betaine or its salts. |
for veterinary use
|
I |
DEC / 13 |
Betaxolol or its salts |
|
I |
DEC / 13 |
Bethanechol chloride |
|
I |
DEC / 13 |
Bethanidine or its salts |
|
I |
DEC / 13 |
Bevacizumab |
|
I |
DEC / 13 |
Bezafibrate or its salts or derivatives |
|
I |
DEC / 13 |
Bicalutamide |
|
I |
DEC / 13 |
Bictegravir or its salts |
|
I |
AUG / 18 |
Bilastine or its salts or derivatives |
|
I |
AUG / 16 |
Biperiden or its salts |
|
I |
DEC / 13 |
Bisacodyl |
when sold in concentrations of 5mg or less per oral dosage unit or 10mg or less per rectal dosage unit/suppository, in package sizes containing no more than 50mg of bisacodyl |
U |
JAN / 14 |
Bisacodyl and its salts |
(except when sold in concentrations of 5mg or less per oral dosage unit or 10mg or less per rectal dosage unit/suppository in package sizes containing no more than 50mg of bisacodyl)
|
III |
JAN / 14 |
Bishydroxycoumarin or its salts or derivatives |
|
I |
DEC / 13 |
Bisoprolol or its salts |
|
I |
DEC / 13 |
Bitolterol or its salts |
|
I |
DEC / 13 |
Bivalirudin |
|
I |
DEC / 13 |
Bleomycin |
|
I |
DEC / 13 |
Blinatumomab |
|
I |
AUG / 16 |
Boceprevir or its derivatives |
|
I |
DEC / 13 |
Boric acid and its salts |
in preparations for systemic use, or ophthalmic preparations in concentrations over 2%[Note: does not apply to contact lens solutions intended to be rinsed off prior to insertion in the eye] |
II |
DEC / 98 |
Bortezomib |
|
I |
DEC / 13 |
Bosentan or its salts or derivatives |
|
I |
DEC / 13 |
Bosutinib or its salts |
including but not limited to Bosutinib methanoate
|
I |
AUG / 14 |
Botulinum toxin |
including but not limited to onabotulinumtoxin A, incobotulinumtoxin A, abobotulinumtoxin A, rimabotulinumtoxin B, prabotulinumtoxin A
|
I |
DEC / 13 |
Brentuximab vedotin |
|
I |
DEC / 13 |
Bretylium tosylate |
|
I |
DEC / 13 |
Brexpiprazole or its salts |
|
I |
APR / 17 |
Brigatinib or its salts |
|
I |
AUG / 18 |
Brimonidine or its salts |
|
I |
DEC / 13 |
Brivaracetam or its derivatives |
|
I |
AUG / 16 |
Brodalumab |
|
I |
MAY / 18 |
Brolucizumab |
|
I |
JUL / 20 |
Bromal |
|
I |
DEC / 13 |
Bromal hydrate |
|
I |
DEC / 13 |
Brometone |
|
I |
DEC / 13 |
Bromfenac or its salts |
|
I |
MAY / 15 |
Bromisoval |
|
I |
DEC / 13 |
Bromocriptine or its salts |
|
I |
DEC / 13 |
Bromoform |
|
I |
DEC / 13 |
Brompheniramine and its salts |
as a single entity for the treatment of allergies |
III |
JAN / 03 |
Brompheniramine and its salts. |
in combination products for the relief of cough and cold symptoms |
U |
JAN / 03 |
Buclizine |
|
II |
SEP / 98 |
Bufexamac |
|
II |
SEP / 98 |
Bumetanide or its salts or derivatives |
|
I |
DEC / 13 |
Bupivacaine and its salts |
for topical use on mucous membranes except lozenges |
III |
SEP / 98 |
Bupivacaine and its salts |
for parenteral or ophthalmic use |
II |
SEP / 98 |
Bupropion or its salts |
|
I |
DEC / 13 |
Burosumab |
|
I |
DEC / 18 |
Buserelin or its salts |
|
I |
DEC / 13 |
Buspirone or its salts |
|
I |
DEC / 13 |
Busulfan |
|
I |
DEC / 13 |
Butacaine and its salts |
for ophthalmic or parenteral use |
II |
SEP / 98 |
Butaperazine or its salts |
|
I |
DEC / 13 |
Butenafine |
1% cream |
U |
SEP / 99 |
Butoconazole or its salts |
|
I |
DEC / 13 |
Butorphanol and its salts C |
|
I |
JUN / 02 |
Butyl chloral hydrate |
|
I |
DEC / 13 |
Cabergoline or its salts |
|
I |
DEC / 13 |
Cabotegravir or its salts |
|
I |
JUL / 20 |
Cabozantinib or its salts |
|
I |
NOV / 18 |
Calcifediol |
|
I |
JUL / 18 |
Calcipotriol |
|
I |
DEC / 13 |
Calcitonin |
|
I |
DEC / 13 |
Calcitriol |
|
I |
DEC / 13 |
Calcium bromide |
|
I |
DEC / 13 |
Calcium bromolactobionate |
|
I |
DEC / 13 |
Calcium carbimide |
|
I |
DEC / 13 |
Calcium chloride in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Calcium disodium edetate |
|
II |
SEP / 98 |
Calcium gluconate in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Calcium polycarbophil |
|
III |
SEP / 98 |
Calcium salts when sold for the treatment of hyperphosphatemia |
|
I |
DEC / 13 |
Camphor |
in oleaginous vehicles and in liquid forms in concentrations greater than 11% |
II |
OCT / 98 |
Canagliflozin |
|
I |
JUL / 14 |
Canakinumab |
|
I |
DEC / 13 |
Candesartan or its salts or derivatives |
including but not limited to candesartan cilexetil
|
I |
DEC / 13 |
Candicidin or its salts or derivatives |
|
I |
DEC / 13 |
Cantharides, their preparations and derivatives |
|
II |
SEP / 98 |
Caplacizumab |
|
I |
JUL / 20 |
Capreomycin or its salts ir deriviatives |
|
I |
DEC / 13 |
Captodiamine or its salts |
|
I |
DEC / 13 |
Captopril or its salts |
|
I |
DEC / 13 |
Carbachol |
|
I |
DEC / 13 |
Carbamazepine |
|
I |
DEC / 13 |
Carbapenem salts or derivatives |
Including but not limited to: Doripenem, ertapenem, imipenem, meropenem
|
I |
DEC / 18 |
Carbenoxolone or its salts |
|
I |
DEC / 13 |
Carbetocin or its salts |
|
I |
DEC / 13 |
Carbidopa or its salts |
|
I |
DEC / 13 |
Carbimazole |
|
I |
DEC / 13 |
Carbinoxamine or its salts |
|
III |
SEP / 98 |
Carbocisteine |
|
I |
DEC / 13 |
Carbomycin or its salts or derivatives |
|
I |
DEC / 13 |
Carboplatin |
|
I |
DEC / 13 |
Carbromal |
|
I |
DEC / 13 |
Carfilzomib |
|
I |
AUG / 16 |
Carglumic acid or its salts or derivatives |
|
I |
JUN / 15 |
Carisoprodol |
|
I |
DEC / 13 |
Carmustine |
|
I |
DEC / 13 |
Carphenazine or its salts |
|
I |
DEC / 13 |
Carprofen or its salts or derivatives |
|
I |
DEC / 13 |
Carvedilol and its salts |
|
I |
DEC / 13 |
Caspofungin or its salts or derivatives |
|
I |
DEC / 13 |
Catumaxomab |
|
I |
DEC / 13 |
Cedazuridine |
When used in combination with another drug.
|
I |
SEP / 20 |
Celecoxib or its salts |
|
I |
DEC / 13 |
Cemiplimab |
|
I |
JUL / 19 |
Cenegermin |
|
I |
MAR / 19 |
Cephalosporin C or its salts or derivatives or analogs |
Including but not limited to: Cephalexin (cefalexin), cephapirin (cefapirin), cefaclor, cefadroxil, cefazolin, cefonicide, cefoxitin, cefprozil, cefuroxime, loracarbef, cefdinir, cefixime, cefoperazone, cefotaxime, cefpodoxime proxetil, ceftazidime, ceftibuten, ceftriaxone, cefepime, ceftobiprole, ceftolozane, cefovecin, ceftiofur
|
I |
DEC / 18 |
Cerapon |
|
III |
SEP / 98 |
Ceritinib or its salts |
|
I |
MAY / 15 |
Cerivastatin or its salts |
|
I |
DEC / 13 |
Cerliponase alfa |
|
I |
FEB / 19 |
Certolizumab pegol |
|
I |
DEC / 13 |
Cetirizine or its salts |
see hydroxyzine or its salts or derivatives
|
I |
DEC / 13 |
Cetirizine or its salts. |
in concentrations of 10 mg equivalent to 8.5 mg or less of cetirizine base per dosage unit, in products marketed for pediatric use (under 12 years of age) |
III |
JUL / 02 |
Cetirizine or its salts.. |
in concentrations of 10mg equivalent to 8.5mg or less of cetirizine base per dosage unit) in products marketed for adult use (age 12 and over)
|
U |
JUL / 02 |
Cetrorelix or its salts |
|
I |
DEC / 13 |
Cetuximab |
|
I |
DEC / 13 |
Charcoal (activated) |
except for use in poisoning treatment |
U |
JUN / 98 |
Charcoal [activated] for use in poisoning treatment |
|
II |
SEP / 98 |
Chlophedianol and its salts |
Clofedanol.
|
III |
SEP / 98 |
Chloral |
|
I |
DEC / 13 |
Chloral hydrate |
|
I |
DEC / 13 |
Chloralformamide |
|
I |
DEC / 13 |
Chloralimide |
|
I |
DEC / 13 |
Chlorambucil or its salts or derivatives |
|
I |
DEC / 13 |
Chloramphenicol or its salts or derivatives |
|
I |
DEC / 13 |
Chlorcyclizine or its salts |
except in preparations for external use
|
I |
DEC / 13 |
Chlorhexidine or its salts |
for human use when used as a topical oral preparation
|
I |
DEC / 13 |
Chlorisondamine or its salts |
|
I |
DEC / 13 |
Chlormezanone |
|
I |
DEC / 13 |
Chloroprocaine and its salts |
for parenteral or ophthalmic use |
II |
SEP / 98 |
Chloroprocaine and its salts |
for topical use on mucous membranes, except lozenges |
III |
SEP / 98 |
Chloroquine or its salts |
|
I |
DEC / 13 |
Chlorothiazide or its salts or derivatives |
for human use
|
I |
DEC / 13 |
Chlorpheniramine and its salts and preparations |
|
U |
AUG / 97 |
Chlorphentermine and any salt thereofC |
|
I |
JUN / 02 |
Chlorpromazine or its salts |
for human use
|
I |
DEC / 13 |
Chlorpropamide |
|
I |
DEC / 13 |
Chlorprothixene or its salts |
|
I |
DEC / 13 |
Chlortetracycline or its salts |
For veterinary use
|
I |
DEC / 18 |
Chlorzoxazone and its salts |
|
III |
SEP / 98 |
Cholecystokinin |
|
II |
SEP / 98 |
Cholera vaccine |
except oral, inactivated, when used for prophylaxis against travellers' diarrhea & due to enterotoxigenic escherichia coli (ETEC) |
I |
JAN / 04 |
Cholera vaccine (oral, inactivated) |
when used for prophylaxis against travellers' diarrhea & due to enterotoxigenic escherichia coli (ETEC) |
II |
JAN / 04 |
Cholestyramine resin |
for human use
|
I |
DEC / 13 |
Choline bitartrate |
parenteral |
II |
SEP / 98 |
Choline salicylate |
when sold in combination with magnesium salicylate
|
I |
DEC / 13 |
Choline theophyllinate |
|
I |
DEC / 13 |
Choriogonadotropin alfa |
|
I |
DEC / 13 |
Chromium Chloride (chromic chloride) in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Chymopapain |
parenteral |
II |
SEP / 98 |
Chymotrypsin |
parenteral and ophthalmic |
II |
SEP / 98 |
Ciclesonide |
For veterinary use
|
I |
JUL / 20 |
Ciclopirox or its salts |
|
I |
DEC / 13 |
Cidofovir or its salts or its derivatives |
|
I |
MAY / 18 |
Cilastatin or its salts |
|
I |
DEC / 13 |
Cilazapril or its salts or derivatives |
|
I |
DEC / 13 |
Cimetidine or its salts |
for veterinary use
|
I |
DEC / 13 |
Cimetidine or its salts. |
except when sold in concentrations of 200 milligrams or less per oral dosage unit and indicated for the treatment of heartburn
|
I |
DEC / 13 |
Cimetidine or its salts.. |
when sold in concentrations of 100 mg or less per dosage unit and indicated for the treatment of heartburn
|
III |
DEC / 13 |
Cinacalcet or its salts |
|
I |
DEC / 13 |
Cinchocaine (dibucaine) and its salts |
for ophthalmic or parenteral use |
II |
SEP / 98 |
Cinchophene or its salts |
|
I |
DEC / 13 |
Cinnamedrine |
|
U |
|
Cinoxacin |
|
I |
DEC / 13 |
Ciprofloxacin or its salts |
|
I |
DEC / 13 |
Cisapride or its salts |
|
I |
SEP / 98 |
Cisatracurium besilate |
|
I |
DEC / 13 |
Cisplatin |
|
I |
DEC / 13 |
Citalopram or its salts |
|
I |
DEC / 13 |
Cladribine or its salts or derivatives |
|
I |
DEC / 13 |
Clemastine and its salts |
|
III |
SEP / 98 |
Clenbuterol or its salts |
|
I |
DEC / 13 |
Clevidipine or its salts |
|
I |
DEC / 13 |
Clidinium and its salts |
|
II |
SEP / 98 |
Clobetasone butyrate |
when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin |
II |
OCT / 06 |
Clodronic acid or its salts |
|
I |
DEC / 13 |
Clofarabine |
|
I |
DEC / 13 |
Clofibrate |
|
I |
DEC / 13 |
Clomiphene or its salts |
|
I |
DEC / 13 |
Clomipramine or its salts |
|
I |
DEC / 13 |
Clonidine or its salts |
|
I |
DEC / 13 |
Clopidogrel or its salts |
|
I |
DEC / 13 |
Clorazepic acid or its salts |
|
I |
DEC / 13 |
Closantel or its salts |
for veterinary use, including but not limited to closantel sodium
|
I |
AUG / 16 |
Clotiazepam and any salt thereofTS |
|
I |
JUN / 02 |
Clotrimazole and its salts.. |
for human use in preparations for topical use |
U |
DEC / 13 |
Clotrimazole or its salts |
for human use, except in preparations for topical or vaginal use
|
I |
DEC / 13 |
Clotrimazole or its salts. |
for human use in preparations for intra-vaginal use
|
III |
DEC / 13 |
Clozapine or its salts |
|
I |
DEC / 13 |
Coal tar |
in concentrations of more than 10% |
II |
SEP / 98 |
Coal tar. |
in concentrations up to and including 10% |
U |
|
Cobicistat or its salts |
|
I |
DEC / 18 |
Cobimetinib or its salts |
|
I |
AUG / 16 |
Coca (Erythroxylum), its preparations, derivatives, alkaloids and saltsN |
Including: Coca leaves; Cocaine; Ecgonine; but not including 123l-ioflupane
|
I |
JUN / 02 |
Codeine and its salts |
in preparations exempted from the Regulations to the Controlled Drugs and Substances Act |
II |
SEP / 98 |
Colchicine |
|
I |
DEC / 13 |
Colesevelam or its salts |
including but not limited to colesevelam hydrochloride
|
I |
DEC / 13 |
Colestipol or its salts |
|
I |
DEC / 13 |
Colfosceril or its derivatives |
|
I |
DEC / 13 |
Colistin or its salt or derivatives |
including but not limited to colistimethate
|
I |
DEC / 13 |
Collagenase |
when recommend for the debridement of severe burns and skin ulcers
|
I |
DEC / 13 |
Copper chloride (cupric chloride) in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Copper sulfate in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Crisaborole |
|
I |
JUL / 18 |
Crizotinib or its salts or derivatives |
|
I |
DEC / 13 |
Cromoglicic (cromoglycic) acid or its salts |
except sodium cromoglicate (cromoglycate) in solutions for ophthalmic or nasal use in concentrations of 2% or less [*see sodium cromoglicate (cromoglycate)]
|
I |
DEC / 13 |
Crotamiton |
|
II |
SEP / 98 |
Cyclandelate |
|
II |
SEP / 98 |
Cyclazocine and its salts |
|
II |
SEP / 98 |
Cyclizine |
for human use
|
I |
DEC / 13 |
Cyclobenzaprine or its salts |
|
I |
DEC / 13 |
Cyclomethacaine and its salts |
for ophthalmic or parenteral use |
II |
SEP / 98 |
Cyclopentamine and its salts |
|
II |
SEP / 98 |
Cyclopentolate or its salts |
except in products for ophthalmic or parenteral use |
II |
SEP / 98 |
Cyclopentolate or its salts |
in preparations for parenteral or ophthalmic use, except when sold for use in diagnostic procedures to an optometrist registered in a province of Canada
|
I |
DEC / 13 |
Cyclophosphamide |
|
I |
DEC / 13 |
Cycloserine |
|
I |
DEC / 13 |
Cyclosporine |
including but not limited to ciclosporin
|
I |
DEC / 13 |
Cyproheptadine and its salts |
|
II |
SEP / 98 |
Cyproterone acetate |
including but not limited to cyproterone acetate
|
I |
DEC / 13 |
Cysteamine (Mercaptamine) or its salts |
|
I |
AUG / 17 |
Cytarabine or its salts |
|
I |
DEC / 13 |
Cytomegalovirus immune globulins |
|
I |
FEB / 02 |
Dabigatran or its salts or derivatives |
including but not limited to dabigatran etexilate
|
I |
DEC / 13 |
Dabrafenib or its salts |
|
I |
DEC / 13 |
Dacarbazine |
|
I |
DEC / 13 |
Daclatasvir or its salts |
|
I |
OCT / 15 |
Daclizumab |
|
I |
DEC / 13 |
Daclizumab beta |
|
I |
FEB / 17 |
Dacomitinib or its salts |
|
I |
MAR / 19 |
Dactinomycin |
|
I |
DEC / 13 |
Dalbavancin or its salts |
|
I |
OCT / 18 |
Dalfopristin or its salts |
|
I |
DEC / 13 |
Dalteparin or its salts |
|
I |
DEC / 13 |
Danaparoid or its salts or derivatives |
|
I |
DEC / 13 |
Danazol |
|
I |
DEC / 13 |
Danofloxacin or its salts |
|
I |
DEC / 13 |
Danthron |
|
III |
SEP / 98 |
Dantrolene or its salts |
|
I |
DEC / 13 |
Dapagliflozin or its derivatives |
|
I |
MAR / 15 |
Dapiprazole or its salts |
|
I |
DEC / 13 |
Daptomycin |
|
I |
DEC / 13 |
Daratumumab |
|
I |
AUG / 16 |
Darifenacin or its salts |
|
I |
DEC / 13 |
Darolutamide |
|
I |
JUL / 20 |
Darunavir |
|
I |
DEC / 13 |
Dasabuvir or its salts |
|
I |
MAR / 15 |
Dasatanib |
|
I |
DEC / 13 |
Daunorubicin or its salts |
|
I |
DEC / 13 |
Debrisoquin or its salts |
|
I |
DEC / 13 |
Decitabine or its salts |
|
I |
FEB / 19 |
Deferasirox |
|
I |
DEC / 13 |
Deferiprone or its derivatives |
|
I |
MAR / 15 |
Deferoxamine or its salts |
|
I |
DEC / 13 |
Defibrotide or its salts or derivatives |
|
I |
SEP / 17 |
Degarelix or its salts or derivatives |
|
I |
DEC / 13 |
Dehydrocholic acid and its salts |
|
III |
SEP / 98 |
Delavirdine or its salts |
|
I |
DEC / 13 |
Denosumab |
|
I |
DEC / 13 |
Deoxycholic acid or its salts |
when used in an injectable form
|
I |
OCT / 15 |
Deracoxib |
|
I |
DEC / 13 |
Derquantel or its salts |
for veterinary use
|
I |
AUG / 16 |
Deserpidine or its alkaloids or salts |
|
I |
DEC / 13 |
Desflurane |
|
I |
DEC / 13 |
Desipramine or its salts |
|
I |
DEC / 13 |
Desloratadine and its salts and preparations. |
in products marketed for paediatric use - under 12 years of age |
III |
SEP / 05 |
Desloratadine and its salts and preparations. |
in products marketed for adult use - 12 years and older
|
U |
SEP / 05 |
Desmopressin or its salts |
|
I |
DEC / 13 |
Desoxyribonuclease [pancreatic dornase] |
|
II |
SEP / 98 |
Desvenlafaxine or its salts |
including but not limited to desvenlafaxine succinate
|
I |
DEC / 13 |
Detomidine or its salts |
|
I |
DEC / 13 |
Dexbrompheniramine and its salts |
|
III |
SEP / 98 |
Dexchlorpheniramine and its salts |
|
III |
SEP / 98 |
Dexrazoxane or its salts |
|
I |
DEC / 13 |
Dextromethorphan and its salts |
except in oral dosage forms in package sizes containing no more than 300mg DM base or 409.3 DM hydrobromide |
III |
AUG / 02 |
Dextromethorphan and its salts. |
in oral dosage forms in package sizes containing no more than 300 mg DM base or 409.3 DM hydrobromide |
U |
AUG / 02 |
Dextrose |
sclerosing agents |
II |
SEP / 98 |
Dextrose injection |
concentrated solutions for parenteral injection |
I |
JAN / 03 |
Diazoxide or its salts |
|
I |
DEC / 13 |
Dibotermin alfa |
for veterinary use
|
I |
FEB / 14 |
Dichloroacetic acid |
|
I |
DEC / 13 |
Diclofenac diethylamine |
when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days - in concentrations greater than 1.16% and less than or equal to 2.32% - in package sizes containing greater than 2.6g of diclofenac diethylamine |
II |
AUG / 14 |
Diclofenac diethylamine. |
when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days - in concentrations greater than 1.16% and less than or equal to 2.32% - in package sizes containing no more than 2.6g of diclofenac diethylamine
|
III |
AUG / 14 |
Diclofenac diethylamine.. |
when sold as a single medicinal ingredient for topical use on the skin in concentrations of not more than 1.16% for not more than 7 days
|
U |
AUG / 14 |
Diclofenac or its salts |
including (but not limited to): diclofenac diethylamine, diclofenac sodium, diclofenac potassium, except when sold as a single medicinal ingredient for topical use on the skin in a concentration equivalent to 2% or less of diclofenac for not more than 7 days
|
I |
AUG / 14 |
Dicyclomine and its salts |
except for topical use and lozenges |
II |
SEP / 98 |
Didanosine or its salts or derivatives |
|
I |
DEC / 13 |
Diethylbromacetamide |
|
I |
DEC / 13 |
Diethylcarbamazine or its salts |
|
I |
DEC / 13 |
Diethylpropion and any salt thereofC |
|
I |
JUN / 02 |
Diethylstilbestrol or its salts or derivatives |
|
I |
DEC / 13 |
Difloxacin or its salts or derivatives |
|
I |
DEC / 13 |
Diflunisal or its salts |
|
I |
DEC / 13 |
Digitalis lanata or its glycosides |
|
I |
DEC / 13 |
Digitalis purpurea or its glycosides |
|
I |
DEC / 13 |
Digoxin immune Fab |
ovine
|
I |
DEC / 13 |
Dihydroquinidine and its salts |
except phenylbarbiturate |
II |
SEP / 98 |
Dihydrostreptomycin or its salts or derivatives |
For human use
|
I |
DEC / 18 |
Dihydrotachysterol |
for human use
|
I |
DEC / 13 |
Diiodohydroxyquin |
except in preparations for topical use on the skin
|
I |
DEC / 13 |
Diiodohydroxyquin |
for topical use on the skin
|
II |
SEP / 98 |
Diltiazem or its salts |
|
I |
DEC / 13 |
Dimenhydrinate and its salts |
for parenteral use |
II |
SEP / 98 |
Dimenhydrinate and its salts. |
for oral or rectal use [Note: Pharmacists are advised that in areas where there is evidence of abuse or particular concern about abuse, dimenhydrinate products should not be located in a self-selection area of the pharmacy]. |
III |
APR / 99 |
Dimercaprol |
|
I |
DEC / 13 |
Dimethothiazine |
|
III |
SEP / 98 |
Dimethyl sulfoxide |
For human use, when sold for the treatment of interstitial cystitis or scleroderma
|
I |
DEC / 13 |
Dimethyl sulfoxide |
For veterinary use
|
I |
DEC / 13 |
Dimethylfumarate |
|
I |
DEC / 13 |
Dimeticone 100 cSt solution |
50% w/w for topical use in the treatment of head lice |
III |
JAN / 13 |
Dinitrophenol or its salts or derivatives |
|
I |
DEC / 13 |
Dinutuximab |
|
I |
DEC / 18 |
Diperodon and its salts |
except for topical use |
II |
SEP / 98 |
Diphenhydramine and its salts and preparations |
for parenteral use |
II |
SEP / 98 |
Diphenhydramine and its salts and preparations. |
except for parenteral or topical use |
III |
SEP / 98 |
Diphenhydramine and its salts and preparations.. |
for topical use in concentrations of greater than 2% |
II |
MAY / 06 |
Diphenhydramine and its salts and preparations... |
for topical use in concentrations of 2% or less when sold in containers of greater than 300 mg of diphenhydramine hydrochloride |
III |
MAY / 06 |
Diphenhydramine and its salts and preparations... |
for topical use in concentrations of 2% or less when sold in containers of 300 mg or less of diphenhydramine hydrochloride |
U |
OCT / 09 |
Diphenidol or its salts |
|
I |
DEC / 13 |
Diphenylhydantoin (phenytoin) or its salts |
|
I |
SEP / 98 |
Diphenylpyraline |
|
III |
SEP / 98 |
Diphtheria toxoid |
|
II |
DEC / 98 |
Dipivefrin or its salts |
|
I |
DEC / 13 |
Diprophylline or its salts |
|
I |
DEC / 13 |
Dipyridamole |
|
I |
DEC / 13 |
Dirithromycin |
For human use
|
I |
DEC / 13 |
Dirlotapide |
|
I |
DEC / 13 |
Disopyramide or its salts |
|
I |
DEC / 13 |
Disulfiram |
|
I |
DEC / 13 |
Dithranol |
Anthralin |
II |
SEP / 98 |
Dobutamine or its salts |
|
I |
DEC / 13 |
Docetaxel or its derivatives |
including but not limited to cabazitaxel
|
I |
DEC / 13 |
Docusate and its salts |
|
U |
|
Dolasetron or its salts |
|
I |
DEC / 13 |
Dolutegravir or its salts |
|
I |
DEC / 13 |
Domperidone |
|
I |
DEC / 13 |
Donepezil or its salts |
|
I |
DEC / 13 |
Dopamine or its salts |
when sold for administration by injection
|
I |
DEC / 13 |
Doravirine |
|
I |
NOV / 18 |
Dornase alfa |
|
I |
DEC / 13 |
Dorzolamide or its salts |
|
I |
DEC / 13 |
Doxacurium chloride |
|
I |
DEC / 13 |
Doxapram |
|
I |
DEC / 13 |
Doxazosin or its salts |
|
I |
DEC / 13 |
Doxepin or its salts |
|
I |
DEC / 13 |
Doxercalciferol or its derivatives |
|
I |
DEC / 13 |
Doxorubicin or its salts |
|
I |
DEC / 13 |
Doxycycline or its salts or derivatives |
including but not limited to doxycycline hyclate, doxycycline monohydrate
|
I |
DEC / 13 |
Doxylamine or its salts |
except those sold for nausea and vomiting of pregnancy
|
III |
SEP / 98 |
Doxylamine or its salts |
when sold or recommended for use in the nausea or vomiting of pregnancy
|
I |
DEC / 13 |
Droperidol or its salts |
|
I |
DEC / 13 |
Drotrecogin |
|
I |
DEC / 13 |
Dulaglutide |
|
I |
JAN / 16 |
Duloxetine or its salts |
|
I |
DEC / 13 |
Dupilumab |
|
I |
MAR / 18 |
Durvalumab |
|
I |
DEC / 17 |
Dutasteride |
|
I |
DEC / 13 |
Dyclonine |
except for topical use on mucous membranes |
II |
SEP / 98 |
Dyclonine and its salts |
for topical use on mucous membranes, except lozenges |
III |
SEP / 98 |
Econazole or its salts |
|
I |
DEC / 13 |
Ecothiophate or its salts |
|
I |
DEC / 13 |
Ectylurea or its salts |
|
I |
DEC / 13 |
Eculizumab |
|
I |
DEC / 13 |
Edaravone or its derivatives |
|
I |
NOV / 19 |
Edoxaban or its salts |
|
I |
FEB / 17 |
Edrophonium chloride |
|
I |
DEC / 13 |
Efalizumab |
|
I |
DEC / 13 |
Efavirenz |
|
I |
DEC / 13 |
Efinaconazole |
|
I |
DEC / 13 |
Eflornithine or its salts or derivatives |
|
I |
DEC / 13 |
Elagolix or its salts |
|
I |
DEC / 18 |
Elbasvir or its salts |
|
I |
AUG / 16 |
Eletriptan or its salts |
|
I |
DEC / 13 |
Eliglustat or its salts |
|
I |
MAY / 17 |
Elosulfase alfa |
|
I |
AUG / 14 |
Elotuzumab |
|
I |
AUG / 16 |
Eltrombopag or its salts |
including but not limited to eltrombopag olamine
|
I |
DEC / 13 |
Eluxadoline or its salts |
|
I |
APR / 17 |
Elvitegravir or its salts or derivatives |
|
I |
DEC / 18 |
Emamectin or its salts |
including but not limited to emamectin benzoate
|
I |
DEC / 13 |
Embutramide |
|
I |
DEC / 13 |
Emedastine or its salts |
|
I |
DEC / 13 |
Emicizumab |
|
I |
OCT / 18 |
Empagliflozin |
|
I |
OCT / 15 |
Emtricitabine |
|
I |
DEC / 13 |
Emylcamate |
|
I |
DEC / 13 |
Enalapril or its salts or derivatives |
including but not limited to enalapril maleate
|
I |
DEC / 13 |
Enasidenib or its salts |
|
I |
MAR / 19 |
Encephalitis vaccine (Japanese) |
|
I |
FEB / 02 |
Enflurane |
|
I |
DEC / 13 |
Enfuvirtide |
|
I |
DEC / 13 |
Enoxaparin or its salts |
|
I |
DEC / 13 |
Enrofloxacin |
|
I |
DEC / 13 |
Entacapone |
|
I |
DEC / 13 |
Entecavir |
|
I |
DEC / 13 |
Entrectinib or its salts |
|
I |
JUL / 20 |
Enzalutamide |
|
I |
DEC / 13 |
Ephedrine and its salts |
in preparations containing more than 8 mg per unit dose, or with a label recommending more than 8 mg/dose or 32 mg/day, or labelled or implied for use exceeding 7 days, or if indicated for other than nasal congestion.
|
I |
FEB / 02 |
Ephedrine and its salts in combination products |
in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use not more than 7 days, and indicated for nasal congestion. |
III |
APR / 06 |
Ephedrine and its salts in single entity products. |
in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use not more than 7 days, and indicated for nasal congestion. |
II |
APR / 06 |
Epinephrine and its salts |
in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens |
II |
SEP / 99 |
Epinephrine and its salts. |
other than in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens |
I |
SEP / 99 |
Epirubicine or its salts |
|
I |
DEC / 13 |
Eplerenone |
|
I |
DEC / 13 |
Eprosartan or its salts or derivatives |
|
I |
DEC / 13 |
Epsiprantel |
|
I |
DEC / 13 |
Eptifibatide or its salts |
|
I |
DEC / 13 |
Erdafitinib or its salts |
|
I |
NOV / 19 |
Erenumab |
|
I |
OCT / 18 |
Ergot alkaloids or their salts |
for human use
|
I |
DEC / 13 |
Eribulin or its salts or derivatives |
including but not limited to eribulin mesylate
|
I |
DEC / 13 |
Erlotinib or its salts |
|
I |
DEC / 13 |
Ertugliflozin or its derivatives |
|
I |
JUL / 18 |
Erythrityl tetranitrate |
|
I |
SEP / 98 |
Erythromycin or its salts or derivatives |
Including but not limited to: azithromycin, clarithromycin, gamithromycin, telithromycin, tulathromycin
|
I |
DEC / 18 |
Erythropoiesis stimulating hormone |
including but not limited to erythropoietin, darbepoetin alpha, epoetin alfa
|
I |
DEC / 13 |
Escitalopram or its salts |
|
I |
DEC / 13 |
Esdepallethrin/piperonyl butoxide |
|
II |
SEP / 98 |
Eslicarbazepine acetate |
|
I |
AUG / 14 |
Esmolol or its salts |
|
I |
DEC / 13 |
Esomeprazole or its salts |
for veterinary use
|
I |
DEC / 13 |
Esomeprazole or its salts |
For human use, including but not limited to esomeprazole magnesium, EXCEPT when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole
|
I |
NOV / 18 |
Esomeprazole or its salts |
For human use, when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole
|
III |
NOV / 18 |
Estramustine or its salts |
|
I |
DEC / 13 |
Etanercept |
|
I |
DEC / 13 |
Ethacrynic acid |
|
I |
DEC / 13 |
Ethambutol or its salts |
|
I |
DEC / 13 |
Ethanolamine oleate |
|
II |
SEP / 98 |
EthchlorvynolTS |
|
I |
SEP / 98 |
EthinamateTS |
|
I |
SEP / 98 |
Ethionamide or its salts |
|
I |
DEC / 13 |
Ethoheptazine and its salts |
|
II |
SEP / 98 |
Ethomoxane or its salts |
|
I |
DEC / 13 |
Ethotoin or its salts |
|
I |
DEC / 13 |
Ethyl Chloride |
except in trace amounts |
II |
SEP / 98 |
Ethyl trichloramate |
|
I |
DEC / 13 |
Ethylpapaverine and its salts |
|
I |
SEP / 98 |
Etidronic acid or its salts |
|
I |
DEC / 13 |
Etodolac or its salts or derivatives |
|
I |
DEC / 13 |
Etomidate or its salts |
|
I |
SEP / 20 |
Etoposide or its derivatives |
|
I |
DEC / 13 |
Etravirine or its salts |
|
I |
DEC / 13 |
Etretinate |
|
I |
DEC / 13 |
Etryptamine and its salts |
|
I |
SEP / 98 |
Etymemazine or its salts |
|
I |
DEC / 13 |
Evolocumab |
|
I |
JAN / 16 |
Exemestane |
|
I |
DEC / 13 |
Exenatide or its salts |
|
I |
DEC / 13 |
Ezetimibe |
|
I |
DEC / 13 |
Ezogabine or its salts or derivatives |
|
I |
DEC / 13 |
Famciclovir or its salts |
|
I |
DEC / 13 |
Famotidine and its salts. |
For human use - when sold in concentrations of 20 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing more than 600 mg of famotidine.
|
III |
MAY / 08 |
Famotidine and its salts.. |
For human use - when sold in concentrations of 20 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing no more than 600 mg of famotidine.
|
U |
FEB / 07 |
Famotidine or its salts |
For human use - except when sold in concentrations of 20 mg or less per oral dosage unit and indicated for the treatment of heartburn.
|
I |
DEC / 13 |
Famotidine or its salts |
For veterinary use.
|
I |
DEC / 13 |
Fampridine or its salts or derivatives |
|
I |
DEC / 13 |
Febuxostat or its salts or derivatives |
|
I |
DEC / 13 |
Fedratinib or its salts |
|
I |
SEP / 20 |
Felodipine or its salts |
|
I |
DEC / 13 |
Fencamfamin and any salt thereofTS |
|
I |
NOV / 20 |
Fenetylline and any salt thereofC |
|
I |
JAN / 03 |
Fenfluramine or its salts |
Including but not limited to dexfenfluramine.
|
I |
DEC / 13 |
Fenofibrate |
|
I |
DEC / 13 |
Fenoprofen or its salts |
|
I |
DEC / 13 |
Fenoterol or its salts |
|
I |
DEC / 13 |
FenproporexTS |
|
I |
JUN / 02 |
Fentanyls, their salts, derivatives, and analogues and salts of derivatives and analoguesN |
Including: Acetyl-α-methylfentanyl, Alfentanil, Carfentanil, p-Fluorofentanyl, Fentanyl, ß-Hydroxyfentanyl, ß-Hydroxy-3-methylfentanyl, α-Methylfentanyl, α-Methylthiofentanyl, 3-Methylfentanyl, 3-Methylthiofentanyl, Remifentanil, Sufentanil, Thiofentanyl, 4-Anilino-N-phenethylpiperidine (ANPP), its derivatives and analogues and salts of derivatives and analogues
|
I |
JUN / 02 |
Fesoterodine or its salts |
Including but not limited to fesoterodine fumarate.
|
I |
DEC / 13 |
Fexofenadine hydrochloride |
in products marketed for adult use (12 years and older) |
U |
APR / 07 |
Fexofenadine hydrochloride. |
in products marketed for paediatric use (under 12 years of age) |
III |
APR / 07 |
Fibrin |
|
II |
SEP / 98 |
Fibrinolysin |
|
II |
SEP / 98 |
Fidaxomicin or its derivatives |
|
I |
DEC / 13 |
Filgrastim |
|
I |
DEC / 13 |
Finafloxacin or its salts or its derivatives |
|
I |
AUG / 16 |
Finasteride |
|
I |
DEC / 13 |
Fingolimod or its salts or derivatives |
Including but not limited to fingolimod hydrochloride.
|
I |
DEC / 13 |
Firocoxib |
|
I |
DEC / 13 |
Flavoxate or its salts |
|
I |
DEC / 13 |
Flecainide or its salts |
|
I |
DEC / 13 |
Fleroxacin or its salts or derivatives |
|
I |
DEC / 13 |
Flibanserin or its salts |
|
I |
MAY / 18 |
Floctafenine |
|
I |
DEC / 13 |
Florfenicol or its derivatives |
|
I |
DEC / 13 |
Fluconazole |
For veterinary use.
|
I |
DEC / 13 |
Fluconazole |
For human use - except when sold in a concentration of 150 mg per oral dosage unit and indicated for the treatment of vaginal candidiasis.
|
I |
DEC / 13 |
Fluconazole |
For human use - when sold in a concentration of 150 mg per oral dosage unit and indicated for the treatment of vaginal candidiasis, in package sizes containing no more than 150 mg of fluconazole.
|
III |
MAR / 10 |
Flucytosine |
|
I |
DEC / 13 |
Fludarabine or its salts or derivatives |
|
I |
DEC / 13 |
Flumazenil |
|
I |
SEP / 98 |
Flunarizine or its salts |
|
I |
DEC / 13 |
Flunitrazepam and any salts or derivatives thereofTS |
|
I |
JUN / 02 |
Flunixin or its salts or derivatives |
Including but not limited to flunixin meglumine.
|
I |
DEC / 13 |
Fluoride or its salts (see sodium fluoride) |
For human use - in solid oral dosage forms containing more than 1 mg of fluoride ion.
|
I |
DEC / 13 |
Fluorouracil or its derivatives |
Including but not limited to capecitabine, tegafur.
|
I |
DEC / 13 |
Fluoxetine or its salts |
|
I |
DEC / 13 |
Flupentixol or its salts or derivatives |
Including but not limited to flupentixol decanoate.
|
I |
DEC / 13 |
Fluphenazine or its salts |
|
I |
DEC / 13 |
Fluralaner |
|
I |
JUN / 14 |
Flurbiprofen or its salts |
|
I |
DEC / 13 |
Fluspirilene |
|
I |
DEC / 13 |
Flutamide |
|
I |
DEC / 13 |
Fluticasone propionate |
When sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 18 years of age and older, in package sizes containing no more than 360 metered sprays.
|
III |
JAN / 20 |
Fluticasone propionate |
When sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 18 years of age and older, in package sizes containing more than 360 metered sprays.
|
II |
JAN / 20 |
Fluvastatin or its salts or derivatives |
|
I |
DEC / 13 |
Fluvoxamine or its salts |
|
I |
DEC / 13 |
Folic acid |
For human use - in oral dosage form containing more than 1.0 milligram of folic acid per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 1.0 milligram of folic acid.
|
I |
DEC / 13 |
Follicle stimulating hormone |
including but not limited to: follitropin alpha, follitropin beta, follitropin delta
|
I |
DEC / 13 |
Fomepizole or its salts |
|
I |
DEC / 13 |
Fondaparinux sodium |
|
I |
DEC / 13 |
Formestane or its derivatives |
|
I |
DEC / 13 |
Formoterol or its salts |
|
I |
DEC / 13 |
Foscarnet sodium |
|
I |
DEC / 13 |
Fosfomycin or its salts |
|
I |
DEC / 13 |
Fosinopril or its salts |
|
I |
DEC / 13 |
Fosphenytoin or its salts |
|
I |
DEC / 13 |
Fostamatinib or its saltsPDL |
|
I |
DEC / 20 |
Fractar |
|
III |
SEP / 98 |
Framycetin or its salts or derivatives |
For human use.
|
I |
DEC / 13 |
Fremanezumab |
|
I |
JUL / 20 |
Frovatriptan or its salts |
|
I |
DEC / 13 |
Fulvestrant |
|
I |
DEC / 13 |
Furaltadone or its salts |
For human use.
|
I |
DEC / 13 |
Furazolidone or its salts |
For human use.
|
I |
DEC / 13 |
Furosemide |
For human use.
|
I |
DEC / 13 |
Fusidic acid or its salts |
|
I |
DEC / 13 |
Gabapentin or its salts or derivatives |
|
I |
DEC / 13 |
Galantamine or its salts or derivatives |
|
I |
DEC / 13 |
Galcanezumab |
|
I |
OCT / 19 |
Gallamine triethiodide |
|
I |
DEC / 13 |
Gallium or its salts |
|
I |
DEC / 13 |
Galsulfase |
|
I |
DEC / 13 |
Gamithromuycin |
|
I |
DEC / 13 |
Ganciclovir or its salts |
|
I |
DEC / 13 |
Ganirelix or its salts or derivatives |
Including but not limited to ganirelix acetate.
|
I |
DEC / 13 |
Gatifloxacin or its salts or derivatives |
|
I |
DEC / 13 |
Gefitinib |
|
I |
DEC / 13 |
Gemcitabine or its salts |
|
I |
DEC / 13 |
Gemfibrozil or its salts |
|
I |
DEC / 13 |
Gemifloxacin or its salts |
|
I |
DEC / 13 |
Gemtuzumab ozogamicin |
|
I |
FEB / 20 |
Gentamicin or its salts or derivatives |
Including but not limited to netilmicin.
|
I |
DEC / 13 |
Gentian Violet |
|
II |
DEC / 01 |
Gilteritinib or its salts |
|
I |
FEB / 20 |
Givosiran or its saltsPDL |
|
I |
DEC / 20 |
Glasdegib or its salts |
|
I |
JUL / 20 |
Glatiramer or its salts |
|
I |
DEC / 13 |
Glecaprevir |
|
I |
SEP / 17 |
Gliclazide |
|
I |
DEC / 13 |
Glimepiride |
|
I |
DEC / 13 |
Glipizide |
|
I |
DEC / 13 |
Glucagon |
|
II |
SEP / 98 |
GlutethimideC |
|
I |
SEP / 98 |
Glyburide or its salts or derivatives |
|
I |
DEC / 13 |
Glyceroargentinate |
|
III |
SEP / 98 |
Glycopyrrolate or its salts |
except glycopyrronium bromide, including but not limited to glycopyrrolate, when used orally or for inhalation
|
II |
DEC / 17 |
Glycopyrronium bromide |
Including but not limited to glycopyrrolate, when used orally or for inhalation.
|
I |
DEC / 17 |
Gold or its salts or derivatives |
Including but not limited to aurothioglucose, auranofin and sodium aurothiomalate, when sold for administration by injection.
|
I |
DEC / 13 |
Golimumab |
|
I |
DEC / 13 |
Gonadorelin or its salts |
|
I |
DEC / 13 |
Gonadotropin releasing factor or its analogues |
For veterinary use.
|
I |
DEC / 13 |
Gonadotropin, chorionic (human) |
|
I |
DEC / 13 |
Gonadotropins, serum (human) |
|
I |
DEC / 13 |
Goserelin or its salts |
|
I |
DEC / 13 |
Gramicidin and its salts |
for topical use |
U |
|
Gramicidin and its salts and derivatives |
for ophthalmic use |
III |
JUN / 06 |
Granisetron or its salts |
|
I |
DEC / 13 |
Grapiprant or its salts |
For veterinary use
|
I |
FEB / 19 |
Grazoprevir |
|
I |
AUG / 16 |
Grepafloxacin or its salts or derivatives |
|
I |
DEC / 13 |
Griseofulvin or its salts or derivatives |
For human use.
|
I |
DEC / 13 |
Guaifenesin |
|
U |
|
Guanethidine or its salts |
|
I |
DEC / 13 |
Guanfacine or its salts or derivatives |
|
I |
DEC / 13 |
Guselkumab |
|
I |
MAR / 18 |
Haemophilus influenzae type B vaccine |
|
II |
DEC / 98 |
Halofantrine or its salts |
|
I |
DEC / 13 |
Halofuginone or its salts |
For veterinary use.
|
I |
MAY / 18 |
Haloperidol |
|
I |
DEC / 13 |
Haloprogin |
|
III |
SEP / 98 |
Halothane |
|
I |
DEC / 13 |
Hemin |
|
I |
AUG / 18 |
Heparin and its salts. |
except for topical use |
II |
SEP / 99 |
Hepatitis A vaccine |
|
I |
FEB / 02 |
Hepatitis B Adult vaccine |
|
I |
FEB / 02 |
Hepatitis B Pediatric vaccine |
|
II |
DEC / 98 |
Hepatitis B immune globulin |
|
I |
FEB / 02 |
Hetacillin or its salts or derivatives |
For veterinary use.
|
I |
DEC / 13 |
Hetastarch or its derivatives |
|
I |
DEC / 13 |
Hexachlorophene or its salts |
|
I |
DEC / 13 |
Hexacyclonate sodium |
|
I |
DEC / 13 |
Hexamethonium or its salts |
|
I |
DEC / 13 |
Histamine and its salts |
except for topical use |
II |
SEP / 98 |
Histrelin or its salts |
|
I |
DEC / 13 |
Homatropine and its salts |
for oral use in concentrations of 2 mg or less per dosage unit |
II |
SEP / 98 |
Homatropine and its salts |
for ophthalmic or parenteral use or in preparations for oral use containing more than 2 mg per dosage unit |
I |
SEP / 98 |
Human insulin |
|
II |
SEP / 98 |
Hyaluronic acid and its salts |
preparations in concentrations of 5% or more |
II |
SEP / 98 |
Hyaluronic acid or its salts |
For veterinary use - when sold or recommended for administration by intra-articular injection to horses.
|
I |
DEC / 13 |
Hyaluronidase |
|
II |
SEP / 98 |
Hydralazine or its salts |
|
I |
DEC / 13 |
Hydrocortisone aceponate |
For veterinary use.
|
I |
DEC / 13 |
Hydrocortisone or hydrocortisone acetate |
When sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin in children under 2 years of age.
|
I |
DEC / 14 |
Hydrocortisone or hydrocortisone acetate. |
When sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin in adults and children 2 years of age and over in package sizes containing more than 30 g.
|
I |
DEC / 14 |
Hydroquinone or its derivatives |
When sold in a concentration less than or equal to 2% in preparations for topical use on the skin
|
II |
JUN / 19 |
Hydroquinone or its derivatives |
When sold in a concentration greater than 2% in preparations for topical use on the skin.
|
I |
JUN / 19 |
Hydroxocobalamin or its salts |
When recommended as an antidote for cyanide poisoning.
|
I |
DEC / 13 |
Hydroxychloroquine or its salts |
|
I |
DEC / 13 |
Hydroxycoumarin or its derivatives |
Including but not limited to acenocoumarol when sold or recommended as anticoagulants.
|
I |
DEC / 13 |
Hydroxyephedrine and its salts |
|
II |
SEP / 98 |
Hydroxyurea |
|
I |
DEC / 13 |
Hydroxyzine or its salts or derivatives |
Including but not limited to cetirizine and hydroxyzine hydrochloride. cetirizine or its salts when sold in concentration greater than 8.5 milligrams cetirizine per unit dose.
|
I |
DEC / 13 |
Hyoscine and its salts and derivatives [scopolamine] |
except Hyoscine butylbromide, when recommended for parenteral use |
II |
AUG / 16 |
Hyoscine butylbromide |
When recommended for parenteral use.
|
I |
AUG / 16 |
Hyoscyamine and its salts and derivatives |
except for topical use |
II |
SEP / 98 |
Ibafloxacin |
|
I |
DEC / 13 |
Ibandronic acid or its salts |
|
I |
DEC / 13 |
Ibogaine or its salts or derivatives or analogues |
|
I |
MAY / 17 |
Ibrutinib or its salts |
|
I |
DEC / 14 |
Ibuprofen or its salts |
For veterinary use.
|
I |
DEC / 13 |
Ibuprofen or its salts |
For human use - except when sold in an oral dosage form that provides 400 mg or less per dosage unit or in a modified-release oral dosage form that provides 600 mg or less per dosage unit.
|
I |
AUG / 16 |
Ibuprofen or its salts. |
when sold in an immediate release dosage form containing 400 mg or less per oral dosage unit (in package sizes exceeding 18,000 mg) |
III |
FEB / 12 |
Ibuprofen or its salts.. |
when sold in a modified-release oral dosage form that provides 600 mg or less per dosage unit
|
III |
AUG / 16 |
Ibuprofen or its salts... |
when sold in an immediate release dosage form containing 400 mg or less per oral dosage unit (in package sizes of up to 18,000 mg) |
U |
FEB / 12 |
Ibutilide or its salts or derivatives |
|
I |
DEC / 13 |
Icatibant or its salts |
Including but not limited to Icatibant acetate.
|
I |
AUG / 14 |
Icosapent ethyl |
For veterinary use.
|
I |
FEB / 20 |
Icosapent ethyl |
For human use: when sold or recommended to reduce the risk of cardiovascular events in statin-treated patients with elevated triglycerides.
|
I |
FEB / 20 |
Idarubicin or its salts |
|
I |
DEC / 13 |
Idarucizumab |
|
I |
AUG / 16 |
Idebenone |
|
I |
DEC / 13 |
Idelalisib |
|
I |
MAY / 15 |
Idoxuridine |
|
I |
DEC / 13 |
Idursulfase |
|
I |
DEC / 13 |
Ifosfamide |
|
I |
DEC / 13 |
Imatinib or its salts |
|
I |
DEC / 13 |
Imidapril or its salts |
|
I |
DEC / 13 |
Imiglucerase |
|
I |
DEC / 13 |
Imipramine or its salts |
|
I |
DEC / 13 |
Imiquimod or its salts |
|
I |
DEC / 13 |
Immune globulin products |
|
I |
FEB / 02 |
Immunogenic substances |
When recommended for sublingual use, including but not limited to: anthoxanthium odoratum L. (sweet vernal grass), betula verrucosa (white birch), dactylis glomerata L. (cocksfoot), lolium perenne L. (rye grass), phleum pratense L. (timothy grass), poa pratense L. (meadow grass).
|
I |
JUL / 20 |
Indacaterol or its salts or derivatives |
|
I |
DEC / 13 |
Indapamide or its salts |
|
I |
DEC / 13 |
Indinavir or its salts |
|
I |
DEC / 13 |
Indomethacin |
|
I |
DEC / 13 |
Infliximab |
|
I |
DEC / 13 |
Influenza vaccine |
|
II |
DEC / 98 |
Ingenol mebutate or its derivatives |
|
I |
DEC / 13 |
Inhaled human insulin |
|
I |
DEC / 13 |
Inosiplex |
|
I |
DEC / 13 |
Inotersen or its salts |
|
I |
NOV / 18 |
Inotuzumab ozogamicin |
|
I |
MAY / 18 |
Insulin |
|
II |
SEP / 98 |
Interferon |
|
I |
DEC / 13 |
Iodinated glycerol |
|
II |
SEP / 98 |
Iodine and its salts and derivatives |
except topical preparations or in oral doses of 1 mg or less per day |
II |
DEC / 98 |
Iodochlorhydroxyquin |
for topical use |
II |
SEP / 98 |
Iodochlorohydroxyquin |
For veterinary use.
|
I |
DEC / 13 |
Iodochlorohydroxyquin |
For human use - except in preparations for topical use on the skin.
|
I |
DEC / 13 |
Ipecac and its extracts and derivatives |
when used as an emetic |
II |
OCT / 98 |
Ipilimumab |
|
I |
DEC / 13 |
Ipratropium or its salts |
|
I |
DEC / 13 |
Iproniazid or its salts |
|
I |
DEC / 13 |
Irbesartan or its salts |
|
I |
DEC / 13 |
Irinotecan or its salts |
|
I |
DEC / 13 |
Iron and its salts and derivatives |
in preparations with more than 30 mg elemental iron per solid dosage unit or 5 mL oral liquid |
II |
SEP / 98 |
Iron derivatives |
For human use - including but not limited to ferumoxytol, iron isomaltoside 1000, for parenteral use only.
|
I |
DEC / 13 |
Iron derivatives |
For veterinary use - including but not limited to ferumoxytol, for all routes of administration but parenteral.
|
I |
DEC / 13 |
Isatuximab |
|
I |
JUL / 20 |
Isavuconazole or its salts |
|
I |
FEB / 19 |
Isocarboxazid or its salts |
|
I |
DEC / 13 |
Isoflurane |
|
I |
DEC / 13 |
Isoniazid |
|
I |
DEC / 13 |
Isopropamide and its salts |
|
I |
SEP / 98 |
Isopropyl myristate in concentration of 50% |
for use in the treatment of head lice
|
III |
JUL / 07 |
Isoproterenol (Isoprenaline) or its salts |
|
I |
DEC / 13 |
Isosorbide and its salts |
|
I |
SEP / 98 |
Isotretinoin or its salts |
|
I |
DEC / 13 |
Isoxsuprine or its salts |
|
I |
DEC / 13 |
Isradipine or its salts |
|
I |
DEC / 13 |
Itraconazole or its salts |
|
I |
DEC / 13 |
Ivabradine or its salts or derivatives |
|
I |
FEB / 17 |
Ivacaftor or its derivatives |
|
I |
DEC / 13 |
Ixazomib or its derivatives |
|
I |
NOV / 16 |
Ixekizumab |
|
I |
AUG / 16 |
Kanamycin or its salts or derivatives |
For human use.
|
I |
DEC / 13 |
Ketanserin or its salts |
|
I |
DEC / 13 |
Ketoconazole and its salts. |
as a shampoo |
U |
|
Ketoconazole or its salts |
For human use - except in preparations for topical use as a shampoo.
|
I |
DEC / 13 |
Ketoconazole or its salts |
For veterinary use
|
I |
DEC / 13 |
Ketoprofene or its salts |
|
I |
DEC / 13 |
Ketorolac or its salts |
|
I |
DEC / 13 |
Ketotifen or its salts |
|
I |
DEC / 13 |
L-Tryptophan |
when sold, a) for human use in oral dosage form at a concentration of more than 220 mg per dosage unit or per daily dose, as a single ingredient or in combination with other indredients; or b) for human or veterinary use as a single ingredient inteded for any route of administration other than oral
|
I |
DEC / 13 |
Labetalol or its salts |
|
I |
DEC / 13 |
Lacosamide or its derivatives |
|
I |
DEC / 13 |
Lactic acid |
When recommended for parenteral use as a tissue sclerosing agent.
|
I |
DEC / 13 |
Lactulose |
|
III |
SEP / 98 |
Lamivudine or its salts |
|
I |
DEC / 13 |
Lamotrigine or its salts |
|
I |
DEC / 13 |
Lanadelumab |
|
I |
NOV / 18 |
Lanreotide or its salts |
|
I |
DEC / 13 |
Lansoprazole or its salts |
|
I |
DEC / 13 |
Lanthanum salts |
For human use - when sold for the treatment of hyperphosphatemia.
|
I |
DEC / 13 |
Lapatinib or its salts |
|
I |
DEC / 13 |
Laronidase |
|
I |
DEC / 13 |
Larotrectinib or its salts |
|
I |
OCT / 19 |
Ledipasvir or its salts |
|
I |
DEC / 14 |
Lefamulin or its salts |
|
I |
SEP / 20 |
Lefetamine, its salts, derivatives and isomers and salts of derivatives and isomersC |
|
I |
JAN / 03 |
Leflunomide or its salts or derivatives |
Including but not limited to teriflunomide.
|
I |
DEC / 13 |
Lemborexant or its saltsPDL |
|
I |
DEC / 20 |
Lenalidomide |
|
I |
DEC / 13 |
Lenvatinib or its salts |
|
I |
AUG / 16 |
Letermovir or its salts |
|
I |
DEC / 17 |
Letrozole |
|
I |
DEC / 13 |
Leucovorin or its salts |
|
I |
DEC / 13 |
Leuprolide or its salts |
|
I |
DEC / 13 |
Levallorphane and its salts |
|
I |
SEP / 98 |
Levamisole or its salts |
For human use.
|
I |
DEC / 13 |
Levargorphane and its salts |
|
II |
SEP / 98 |
Levetiracetam |
|
I |
DEC / 13 |
Levobunolol or its salts |
|
I |
DEC / 13 |
Levocabastine or its salts or derivatives |
|
I |
DEC / 13 |
Levocarnitine or its salts or derivatives |
When sold for the treatment of primary or secondary levocarnitine deficiency.
|
I |
DEC / 13 |
Levodopa or its salts |
|
I |
DEC / 13 |
Levomilnacipran or its salts |
|
I |
JUN / 15 |
Levonordefrine |
|
II |
SEP / 98 |
Levonorgestrel |
when sold in concentrations of 1.5 mg or less per oral dosage unit (except when labelled to be taken as a single dose of 1.5 mg and in package sizes containing no more than 1.5 mg levonorgestrel, packaged and labelled for emergency contraception.) |
II |
MAY / 15 |
Levonorgestrel. |
when sold in concentrations of 1.5 mg or less per oral dosage unit to be taken as a single dose of 1.5 mg, packaged and labelled for emergency contraception, in package sizes containing no more than 1.5 mg of levonorgestrel |
III |
MAY / 15 |
Lidocaine |
For human use - when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher.
|
I |
FEB / 14 |
Lidocaine and its salts |
for ophthalmic or parenteral use, or topical use on mucous membranes, except lozenges |
II |
SEP / 98 |
Lidocaine and its salts. |
for otic use
|
III |
JUN / 06 |
Lidocaine and its salts.. |
for topical use on the skin, including lozenges [except when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher]
|
U |
FEB / 14 |
Lidocaine and prilocaine |
eutectic mixture |
III |
FEB / 99 |
Lifitegrast or its salts |
|
I |
MAR / 18 |
Linaclotide or its salts or derivatives |
|
I |
DEC / 13 |
Linagliptin or its salts or derivatives |
|
I |
DEC / 13 |
Lincomycin or its salts or derivatives |
Including but not limited to: Clindamycin
|
I |
DEC / 18 |
Lindane |
|
II |
SEP / 98 |
Linezolid or its salts |
|
I |
DEC / 13 |
Liothyronine or its salts |
For human use.
|
I |
DEC / 13 |
Lipid solutions in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Liraglutide or its salts |
|
I |
DEC / 13 |
Lisinopril or its salts or derivatives |
|
I |
DEC / 13 |
Lithium or its salts |
|
I |
DEC / 13 |
Lixisenatide or its salts |
|
I |
JUN / 17 |
Lodoxamide or its salts or derivatives |
Including but not limited to Lodoxamide tromethamine.
|
I |
DEC / 13 |
Lomefloxacin or its salts |
|
I |
DEC / 13 |
Lomitapide or its salts |
|
I |
FEB / 14 |
Lomustine |
|
I |
DEC / 13 |
Loperamide and its salts |
in products marketed for adult use (12 years and older) |
U |
APR / 07 |
Loperamide and its salts. |
in products marketed for paediatric use (under 12 years of age) |
II |
APR / 07 |
Lopinavir |
|
I |
DEC / 13 |
Loratadine and its salts and preparations |
in products marketed for paediatric use - under 12 years of age |
III |
OCT / 02 |
Loratadine and its salts and preparations. |
in products marketed for adult use - 12 years and older |
U |
OCT / 02 |
Lorlatinib or its salts |
|
I |
MAR / 19 |
Losartan or its salts |
|
I |
DEC / 13 |
Losoxantrone or its salts |
|
I |
DEC / 13 |
Lotilaner |
For veterinary use.
|
I |
MAR / 18 |
Lovastatin |
Except in oral dosage form that provides 1 milligram (mg) or less per daily dose.
|
I |
DEC / 14 |
Loxapine or its salts |
|
I |
DEC / 13 |
Lumacaftor or its salts or derivatives |
|
I |
AUG / 16 |
Lumiracoxib |
|
I |
DEC / 13 |
Lurasidone or its salts |
|
I |
DEC / 13 |
LuspaterceptPDL |
|
I |
DEC / 20 |
Lutropin alfa |
|
I |
DEC / 13 |
Lyme Disease vaccine |
|
I |
FEB / 02 |
Macitentan or its derivatives |
|
I |
DEC / 13 |
Magnesium glutamate hydrobromide |
|
I |
DEC / 13 |
Magnesium sulfate |
for parenteral use |
II |
SEP / 98 |
Magnesium sulfate in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Manganese and its salts |
In injectable form for parenteral nutrition.
|
I |
JAN / 03 |
Mannitol |
When sold and recommended for use as a diagnostic agent for the assessment of bronchial hyperresponsiveness.
|
I |
OCT / 19 |
Mannitol and its salts |
Except when sold and recommended for use as a diagnostic agent for the assessment of bronchial hyperresponsiveness.
|
II |
OCT / 19 |
Maprotiline or its salts |
|
I |
DEC / 13 |
Maraviroc |
|
I |
DEC / 13 |
Marbofloxacin or its salts or derivatives |
|
I |
DEC / 13 |
Maropitant or its salts |
|
I |
DEC / 13 |
MazindolTS |
|
I |
SEP / 98 |
Measles vaccine |
|
II |
DEC / 98 |
Mebendazole |
For human use.
|
I |
DEC / 13 |
Mebendazole |
For veterinary use - when sold to treat dogs only.
|
I |
DEC / 13 |
Mecamylamine or its salts |
|
I |
DEC / 13 |
Mechlorethamine or its salts |
|
I |
DEC / 13 |
Mecillinam or its salts or derivatives |
For veterinary use.
|
I |
DEC / 13 |
Meclizine and its salts. |
when sold in concentrations of 25 mg or less per dosage unit
|
III |
MAY / 00 |
Meclizine or its salts |
For human use - when sold in concentrations greater than 25 mg per dosage unit.
|
I |
DEC / 13 |
Meclofenamic acid or its salts |
|
I |
DEC / 13 |
Mecloqualone and any salt thereofC |
|
I |
JAN / 03 |
Medetomidine or its salts |
|
I |
DEC / 13 |
Mefenamic acid or its salts |
|
I |
DEC / 13 |
Mefenorex and any salt thereofTS |
|
I |
JUN / 02 |
Mefloquine or its salts or derivatives |
|
I |
DEC / 13 |
Megestrol or its salts |
|
I |
DEC / 13 |
Melanoma therapeutic vaccine |
|
I |
DEC / 13 |
Melarsomine or its salts |
For human use
|
I |
DEC / 13 |
Melarsomine or its salts |
For veterinary use - when sold for the treatment of heartworm in dogs.
|
I |
DEC / 13 |
Meloxicam or its salts or derivatives |
|
I |
DEC / 13 |
Melphalan |
|
I |
DEC / 13 |
Memantine or its salts |
|
I |
DEC / 13 |
Meningococcus vaccine |
|
II |
MAR / 01 |
Menotropins (human) |
|
I |
DEC / 13 |
Mepacrine or its salts |
|
I |
DEC / 13 |
Mepazine or its salts |
|
I |
DEC / 13 |
Mephenoxalone |
|
I |
DEC / 13 |
Mephentermine or its salts |
|
I |
DEC / 13 |
Mepivacaine and its salts |
for topical use on mucous membranes, except lozenges |
III |
SEP / 98 |
Mepivacaine and its salts |
for ophthalmic or parenteral use |
II |
SEP / 98 |
Mepolizumab |
|
I |
AUG / 16 |
MeprobamateTS |
|
I |
SEP / 98 |
Mepyramine |
see pyrilamine |
U |
|
Mercaptopurine |
|
I |
DEC / 13 |
Mesna |
|
I |
DEC / 13 |
Mesocarb and any salt thereofC |
|
I |
JAN / 03 |
Mesoridazine or its salts |
|
I |
DEC / 13 |
Metaldehyde |
|
I |
DEC / 13 |
Metaraminol bitartrate |
|
I |
SEP / 98 |
Metathoheptazine and its salts |
|
II |
SEP / 98 |
Metformin or its salts or derivatives |
|
I |
DEC / 13 |
Methacholine chloride |
|
I |
DEC / 13 |
Methadols, their salts, derivatives and salts of derivativesN |
Including: Acetylmethadol, Alphacetylmethadol, Alphamethadol, Betacetylmethadol, Betamethadol, Dimepheptanol, Noracymethadol
|
I |
JUN / 02 |
Methantheline and its salts |
|
II |
SEP / 98 |
Methaqualone and any salt thereofC |
|
I |
JUN / 02 |
Methazolamide or its salts |
|
I |
DEC / 13 |
Methdilazine and its salts |
|
II |
SEP / 98 |
Methenamine and its salts |
except for topical use |
II |
SEP / 98 |
Metheptazine and its salts |
|
II |
SEP / 98 |
Methicillin or its salts or derivatives |
For veterinary use.
|
I |
DEC / 13 |
Methimazole |
|
I |
DEC / 13 |
Methisazone |
|
I |
DEC / 13 |
Methocarbamol |
for parenteral use |
II |
SEP / 98 |
Methocarbamol. |
except for parenteral use |
III |
SEP / 98 |
Methoin (Mephenytoin) or its salts |
|
I |
DEC / 13 |
Methotrexate or its salts |
|
I |
DEC / 13 |
Methotrimeprazine or its saltsPDL |
|
I |
DEC / 13 |
Methoxamine or its salts |
|
I |
DEC / 13 |
Methoxsalen |
|
I |
DEC / 13 |
Methoxy polyethylene glycol-epoetin beta |
|
I |
DEC / 13 |
Methoxyflurane |
|
I |
MAY / 18 |
Methyl salicylate |
in liquid dosage forms in concentrations greater than 30% |
II |
SEP / 98 |
Methyldopa or its salts |
|
I |
DEC / 13 |
Methylene Blue |
for parenteral use |
II |
SEP / 98 |
Methylnaltrexone or its salts |
Including but not limited to methylnaltrexone bromide.
|
I |
JUN / 15 |
Methylparafynol |
|
I |
DEC / 13 |
Methylphenidate, its salts, derivatives, isomers and analogues and salts of derivatives, isomers and analoguesC |
Including: Ethylphenidate; Isopropylphenidate; Propylphenidate; 3,4-Dichloromethylphenidate; 4-Methylmethylphenidate; 4-Fluoromethylphenidate;
Methylnaphthidate; Ethylnaphthidate
|
I |
JUN / 02 |
MethyprylonTS |
|
I |
SEP / 98 |
Methysergide or its salts or derivatives |
|
I |
DEC / 13 |
Metoclopramide |
|
I |
DEC / 13 |
Metolazone or its salts |
|
I |
DEC / 13 |
Metomidate or its salts |
|
I |
DEC / 13 |
Metopimazine or its salts |
|
I |
DEC / 13 |
Metoprolol or its salts |
|
I |
DEC / 13 |
Metronidazole |
|
I |
DEC / 13 |
Metyrapone or its salts |
|
I |
DEC / 13 |
Mexiletine or its salts |
|
I |
DEC / 13 |
Mezlocillin or its salts or derivatives |
For veterinary use
|
I |
DEC / 13 |
Micafungin or its salts |
|
I |
DEC / 13 |
Miconazole and its salts. |
for vaginal use |
III |
SEP / 98 |
Miconazole and its salts.. |
for topical use |
U |
|
Miconazole or its salts |
For human use - except in preparations for topical or vaginal.
|
I |
DEC / 13 |
Miconazole or its salts |
For veterinary use.
|
I |
DEC / 13 |
Midodrine or its salts |
|
I |
DEC / 13 |
Midostaurin or its salts |
|
I |
SEP / 17 |
Mifepristone or its derivatives |
|
I |
AUG / 15 |
Migalastat or its salts |
|
I |
DEC / 17 |
Miglustat |
|
I |
DEC / 13 |
Milbemycin or its derivatives |
For veterinary use - including but not limited to Moxidectin. Moxidectin when sold for the prevention of heartworm in dogs.
|
I |
DEC / 13 |
Milbemycin or its derivatives |
For human use - including but not limited to moxidectin.
|
I |
DEC / 13 |
Milrinone or its salts |
|
I |
DEC / 13 |
Mineral tar |
except shampoos with concentrations less than 5% |
III |
SEP / 98 |
Minoxidil |
For veterinary use
|
I |
DEC / 13 |
Minoxidil |
except when sold in preparations for topical use in concentrations of 5% or less, for human use only
|
I |
AUG / 14 |
Minoxidil. |
when sold in preparations for topical use in adults in concentrations of 5% or less, for human use only
|
U |
JUL / 17 |
Mirabegron or its salts |
|
I |
DEC / 13 |
Mirtazapine or its salts |
|
I |
DEC / 13 |
Mitomycin or its salts |
|
I |
DEC / 13 |
Mitotane |
|
I |
DEC / 13 |
Mitoxantrone or its salts |
|
I |
DEC / 13 |
Mitratapide |
|
I |
FEB / 14 |
Mivacurium chloride |
|
I |
DEC / 13 |
Moclobemide or its salts or derivatives |
|
I |
DEC / 13 |
Modafinil or its salts |
|
I |
DEC / 13 |
Molgramostim |
|
I |
DEC / 13 |
Mometasone furoateNR |
For the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 12 years of age and older.
|
I |
AUG / 15 |
Monobenzone |
|
II |
SEP / 98 |
Monoethanolamine oleate |
|
II |
SEP / 98 |
Montelukast or its salts |
|
I |
DEC / 13 |
Moramides, their intermediates, salts, derivatives and salts of intermediates and derivativesN |
Including: Dextromoramide, Diphenylmorpholinoisovaleric acid, Levomoramide, Racemoramide
|
I |
JUN / 02 |
Morphinans, their salts, derivatives and salts of derivativesN |
Including: Buprenorphine, Drotebanol, Levomethorphan, Levorphanol, Levophenacylmorphan, Norlevorphanol, Phenomorphan, Racemethorphan, Racemorphan; but not including: Dextromethorphan and its salts, Dextrorphan and its salts, Levallorphan and its salts, Levargorphan and its salts, Butorphanol and its salts, Nalbuphine and its salts
|
I |
JUN / 02 |
Moxifloxacin or its salts or derivatives |
|
I |
DEC / 13 |
Mumps vaccine |
|
II |
DEC / 98 |
Mupirocin |
|
I |
SEP / 99 |
Muromonab-CD3 |
|
I |
DEC / 13 |
Mycophenolic acid or its salts or derivatives |
Including but not limited to Mycophenolate mofetil.
|
I |
DEC / 13 |
Nabumetone |
|
I |
DEC / 13 |
Nadolol or its salts |
|
I |
DEC / 13 |
Nadroparin or its salts |
|
I |
DEC / 13 |
Nafarelin or its salts or derivatives |
Including but not limited to Nafarelin acetate.
|
I |
DEC / 13 |
Nafcillin or its salts or derivatives |
For veterinary use
|
I |
DEC / 13 |
Nalbuphine and any salt thereofC |
|
I |
JUN / 02 |
Nalidixic acid |
|
I |
DEC / 13 |
Nalmefene or its salts |
|
I |
DEC / 13 |
Naloxegol or its salts |
including but not limited to naloxegol oxalate
|
I |
JUN / 15 |
Naloxone hydrochloride injection, |
when indicated for emergency use for opioid overdose
Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.
|
II |
FEB / 17 |
Naloxone hydrochloride nasal spray, |
when indicated for emergency use for opioid overdose
Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.
|
II |
FEB / 17 |
Naloxone or its salts |
including, but not limited to naloxone hydrochloride, except when indicated for emergency use for opioid overdose
|
I |
FEB / 17 |
Naltrexone or its salts |
|
I |
DEC / 13 |
Naphazoline and its salts |
in nasal preparations for pediatric use |
II |
SEP / 98 |
Naphazoline and its salts. |
in nasal preparations for adult use and in ophthalmic products |
U |
|
Naproxen or its salts |
Except in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base).
[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]
|
I |
MAR / 15 |
Naproxen or its salts.. |
In preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes of the equivalent of 6,000 mg of naproxen base or less.
[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]
|
U |
MAR / 15 |
Naproxen or its salts.. |
In preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes exceeding the equivalent of 6,000 mg of naproxen base.
[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]
|
III |
MAR / 15 |
Naratriptan or its salts |
|
I |
DEC / 13 |
Natalizumab |
|
I |
DEC / 13 |
Nateglinide or its salts or derivatives |
|
I |
DEC / 13 |
Nebivolol or its salts or derivatives |
|
I |
DEC / 13 |
Necitumumab |
|
I |
APR / 17 |
Nedocromil or its salts |
|
I |
DEC / 13 |
Nefazodone or its salts |
|
I |
DEC / 13 |
Nelarabine |
|
I |
DEC / 13 |
Nelfinavir or its salts |
|
I |
DEC / 13 |
Neocinchophen or its salts |
|
I |
DEC / 13 |
Neomycin or its salts or derivatives |
Including but not limited to: Paromomycin sulfate (for veterinary use)
|
I |
DEC / 18 |
Neostigmine salts |
|
I |
DEC / 13 |
Nepafenac |
|
I |
DEC / 13 |
Neratinib or its salts |
|
I |
OCT / 19 |
Nesiritide or its salts |
|
I |
DEC / 13 |
Netupitant |
|
I |
DEC / 17 |
Nevirapine or its salts |
|
I |
DEC / 13 |
Niacin (nicotinic acid) |
in extended-release formulations, except when sold in a modified-release oral dosage form that provides 500 milligrams or more per dosage unit or per daily dose
|
II |
MAR / 10 |
Nialamide or its salts |
|
I |
DEC / 13 |
Nicarbazin |
For human use
|
I |
DEC / 13 |
Nicardipine or its salts |
|
I |
DEC / 13 |
Nicotine or its salts |
For human use - EXCEPT: (a) in natural substances; (b) in the form of a chewing gum containing 4 mg or less of nicotine per dosage unit; (c) in the form of a transdermal patch with a delivery rate of 22 mg or less of nicotine per day; (d) in a form to be administered into the oral cavity by means of a non-active device (one that operates on energy generated by the human body or by gravity) that delivers 4 mg or less of nicotine per dose for buccal absorption; or (e) in the form of a lozenge containing 4 mg or less of nicotine per dosage unit).
|
I |
AUG / 18 |
Nicotine or its salts |
For veterinary use.
|
I |
DEC / 13 |
Nicotinic acid |
For human use - when sold in: (a) a modified-release oral dosage form that provides 500 milligrams or more per dosage unit or per daily dose; or (b) an immediate-release oral dosage form that provides more than 500 milligrams per dosage unit or per daily dose.
|
I |
DEC / 13 |
Nicotinyl-tartrate |
|
I |
SEP / 98 |
Nifedipine |
|
I |
DEC / 13 |
Nikethamide |
|
I |
SEP / 98 |
Nilotinib or its salts |
|
I |
DEC / 13 |
Nilutamide |
|
I |
DEC / 13 |
Nimodipine or its salts |
|
I |
DEC / 13 |
Nintedanib or its salts |
|
I |
AUG / 15 |
Niraparib or its salts |
|
I |
OCT / 19 |
Nitisinone |
|
I |
NOV / 16 |
Nitric oxide |
|
I |
DEC / 13 |
Nitrofurantoin or its salts |
For human use.
|
I |
DEC / 13 |
Nitroglycerin |
Except for sublingual immediate release dosage forms.
|
I |
SEP / 98 |
Nitroglycerin. |
sublingual immediate release dosage forms |
II |
SEP / 98 |
Nitroscanate |
|
I |
DEC / 13 |
Nivolumab |
|
I |
JAN / 16 |
Nizatidine and its saltsNR |
When sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine.*
|
I |
SEP / 98 |
Nizatidine or its salts |
Except when sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine.
|
I |
DEC / 13 |
Nomifensine or its salts |
|
I |
DEC / 13 |
Norepinephrine and its salts |
levarterenol, noradrenaline |
II |
SEP / 98 |
Norfloxacin |
|
I |
DEC / 13 |
Nortriptyline or its salts |
|
I |
DEC / 13 |
Novobiocin or its salts or derivatives |
For human use.
|
I |
DEC / 13 |
Nusinersen |
|
I |
AUG / 17 |
Nylidrin or its salts |
|
I |
DEC / 13 |
Nystatin and its salts and derivatives. |
in topical preparations for use on the skin |
III |
SEP / 98 |
Nystatin or its salts or derivatives |
For human use - except preparations for topical use on the skin.
|
I |
DEC / 13 |
Obeticholic acid or its salts |
|
I |
MAY / 17 |
Obiltoxaximab |
|
I |
SEP / 20 |
Obinutuzumab |
|
I |
DEC / 14 |
Oclacitinib or its salts |
including but not limited to Oclacitinib maleate
|
I |
AUG / 14 |
Ocrelizumab |
|
I |
SEP / 17 |
Ocriplasmin |
|
I |
DEC / 13 |
Octatropine methylbromide |
|
I |
DEC / 13 |
Octreotide |
|
I |
DEC / 13 |
Ofatumumab |
|
I |
DEC / 13 |
Ofloxacin or its salts |
Including but not limited to levofloxacin.
|
I |
DEC / 13 |
Olanzapine or its salts |
|
I |
DEC / 13 |
Olaparib |
|
I |
AUG / 16 |
Olaratumab |
|
I |
MAR / 18 |
Oleandomycin or its salts or derivatives |
For human use.
|
I |
DEC / 13 |
Olmesartan or its salts or derivatives |
Including but not limited to olmesartan medoxmil.
|
I |
DEC / 13 |
Olodaterol or its salts |
|
I |
DEC / 13 |
Olopatadine or its salts |
|
I |
DEC / 13 |
Olsalazine or its salts |
|
I |
DEC / 13 |
Omalizumab |
|
I |
DEC / 13 |
Ombitasvir |
|
I |
MAR / 15 |
Omeprazole or its salts |
For human use - including but not limited to omeprazole, omeprazole magnesium except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of omeprazole.
|
I |
SEP / 14 |
Omeprazole or its salts |
For veterinary use - including but not limited to omeprazole, omeprazole magnesium.
|
I |
DEC / 13 |
Omeprazole or its salts. |
when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of omeprazole
|
II |
SEP / 14 |
Ondansetron or its salts |
|
I |
DEC / 13 |
Opium Poppy (Papaver somniferum), its preparations, derivatives, alkaloids and saltsN |
Including: (1) Opium; (2) Codeine; (3) Morphine; (4) Thebaine; and the salts, derivatives and salts of derivatives of the substances set out in subitems (1) to (4), including: Acetorphine; Acetyldihydrocodeine; Benzylmorphine; Codoxime; Desomorphine; Diacetylmorphine (heroin); Dihydrocodeine; Dihydromorphine; Ethylmorphine; Etorphine; Hydrocodone; Hydromorphinol; Hydromorphone; Methyldesorphine; Methyldihydromorphine; Metopon; Morphine-N-oxide; Myrophine; Nalorphine; Nicocodine; Nicomorphine; Norcodeine; Normorphine; Oxycodone; Oxymorphone; Pholcodine; Thebacon; but not including: Apomorphine; Cyprenorphine and its salts; Nalmefene and its salts; Naloxone and its salts; Naltrexone and its salts; Methylnaltrexone and its salts; Naloxegol and its salts; Narcotine and its salts; Papaverine and its salts; Poppy seed
|
I |
JUN / 02 |
Orbifloxacin or its salts or derivatives |
|
I |
DEC / 13 |
Orciprenaline (Metaproterenol) or its salts |
|
I |
DEC / 13 |
Orlistat |
|
I |
DEC / 13 |
Ormetoprim or its salts |
|
I |
DEC / 13 |
Ornidazole |
|
I |
DEC / 13 |
Orphenadrine citrate |
|
III |
SEP / 98 |
Orphenadrine hydrochloride |
|
I |
SEP / 98 |
Oseltamivir or its salts |
|
I |
DEC / 13 |
Osimertinib or its salts |
|
I |
AUG / 16 |
Oxacillin, or its salts or derivatives |
For veterinary use
|
I |
DEC / 13 |
Oxaliplatin |
|
I |
DEC / 13 |
Oxanamide |
|
I |
DEC / 13 |
Oxaprozin or its salts or derivatives |
|
I |
DEC / 13 |
Oxcarbazepine |
|
I |
DEC / 13 |
Oxethazine |
|
III |
SEP / 98 |
Oxiconazole |
1% for topical use |
U |
SEP / 99 |
Oxolinic acid or its salts |
|
I |
DEC / 13 |
Oxprenolol or its salts |
|
I |
DEC / 13 |
Oxybuprocaine and its salts |
benoxinate for opthalmic or parenteral use |
II |
SEP / 98 |
Oxybuprocaine and its salts |
for topical use on mucous membranes, except lozenges |
III |
SEP / 98 |
Oxybutynin or its salts |
|
I |
DEC / 13 |
Oxymetazoline |
in nasal preparations for adult use and in ophthalmic products |
U |
|
Oxymetazoline and its salts |
in nasal preparations for pediatric use |
II |
SEP / 98 |
Oxyphenbutazone or its salts |
|
I |
DEC / 13 |
Oxyquinoline |
|
II |
SEP / 98 |
Oxytetracycline or its salts |
For veterinary use
|
I |
DEC / 18 |
Oxytocin |
|
I |
DEC / 13 |
Ozanimod or its saltsPDL |
|
I |
DEC / 20 |
Ozenoxacin or its salts |
|
I |
JUN / 17 |
Paclitaxel or its derivatives |
|
I |
DEC / 13 |
Palbociclib or its salts |
|
I |
AUG / 16 |
Palifermin |
|
I |
DEC / 13 |
Paliperidone or its salts or its derivatives |
|
I |
DEC / 13 |
Palivizumab |
|
I |
DEC / 13 |
Palonosetron or its salts |
including but not limited to palonosetron hydrochloride
|
I |
DEC / 13 |
Pamidronic acid or its salts |
|
I |
DEC / 13 |
Pancreatic extracts |
when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency
|
I |
DEC / 13 |
Pancreatin |
when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency
|
I |
DEC / 13 |
Pancrelipase |
when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency
|
I |
DEC / 13 |
Pancuronium or its salts |
|
I |
DEC / 13 |
Panitumumab |
|
I |
DEC / 13 |
Pantoprazole or its salts |
|
I |
DEC / 13 |
Papaveretrine or its salts |
|
I |
SEP / 98 |
Papaverine or its salts |
|
I |
SEP / 98 |
Paraldehyde |
|
I |
DEC / 13 |
Paramethadione |
|
I |
DEC / 13 |
Pargyline or its salts |
|
I |
DEC / 13 |
Paricalcitol |
|
I |
DEC / 13 |
Paritaprevir (Veruprevir) |
|
I |
MAR / 15 |
Paroxetine or its salts |
|
I |
DEC / 13 |
Paroxypropione |
|
II |
SEP / 98 |
Pasireotide or its salts |
|
I |
DEC / 13 |
Patiromer sorbitex calcium |
|
I |
NOV / 18 |
Patisiran or its salts |
|
I |
JUL / 19 |
Pazopanib or its salts |
|
I |
DEC / 13 |
Pegaptanib or its salts |
|
I |
DEC / 13 |
Pegaspargase |
|
I |
APR / 17 |
Pegfilgrastim |
|
I |
DEC / 13 |
Pegvisomant |
|
I |
DEC / 13 |
Pembrolizumab |
|
I |
JUN / 15 |
Pemetrexed or its salts |
|
I |
DEC / 13 |
Pemoline and any salt thereofC |
|
I |
JAN / 03 |
Penciclovir or its salts |
|
I |
DEC / 13 |
Penicillamine |
|
I |
DEC / 13 |
Penicillin or its salts or derivatives |
Including but not limited to:
Amoxicillin, ampicillin, azlocillin, benzathine penicillin, carbenicillin, cloxacillin, dicloxacillin, hetacillin, mecillinam, methicillin, mezlocillin, nafcillin, oxacillin, ticarcillin, penicillin G (benzyl penicillin), procaine penicillin G.
|
I |
DEC / 18 |
Pentaerythritol tetranitrate |
|
I |
SEP / 98 |
Pentagastrin and its salts |
|
II |
SEP / 98 |
Pentamidine or its salts |
|
I |
DEC / 13 |
PentobarbitalC |
|
I |
JUN / 02 |
Pentolinium tartrate |
|
I |
DEC / 13 |
Pentosan polysulfate or its salts |
|
I |
DEC / 13 |
Pentostatin or its salts |
|
I |
DEC / 13 |
Pentoxifylline or its salts |
|
I |
DEC / 13 |
Peramivir or its salts or derivatives |
|
I |
MAR / 17 |
Perampanel |
|
I |
DEC / 13 |
Perflutren |
|
I |
DEC / 13 |
Pergolide or its salts |
|
I |
DEC / 13 |
Pericyazine or its salts |
|
I |
DEC / 13 |
Perindopril or its salts |
|
I |
DEC / 13 |
Permethrin and its derivatives |
|
II |
SEP / 98 |
Permethrin or its derivatives |
For veterinary use, when recommended in cats.
|
I |
DEC / 13 |
Perphenazine or its salts |
|
I |
DEC / 13 |
Pertussis vaccine |
|
II |
DEC / 98 |
Pertuzumab |
|
I |
DEC / 13 |
Phacetoperane or its salts |
|
I |
DEC / 13 |
Phenacemide |
|
I |
DEC / 13 |
Phenacetin |
|
I |
DEC / 13 |
Phenaglycodol |
|
I |
DEC / 13 |
Phenalkoxams, their salts, derivatives and salts of derivativesN |
Including: Dimenoxadol, Dioxaphetyl butyrate, Dextropropoxyphene
|
I |
JUN / 02 |
Phenazepines, their salts, derivatives and salts of derivativesN |
Including: Proheptazine; but not including: Ethoheptazine and its salts; Metethoheptazine and its salts; Metheptazine and its salts
|
I |
JUN / 02 |
Phenazopyridine or its salts |
|
I |
DEC / 13 |
Phencyclidine, its salts, derivatives and analogues and salts of derivatives and analoguesN |
Including: Ketamine
|
I |
JUN / 02 |
Phendimetrazine and any salt thereofC |
|
I |
JUN / 02 |
Phenelzine or its salts |
|
I |
DEC / 13 |
Phenformin and its salts |
|
I |
DEC / 13 |
Pheniprazine or its salts |
|
I |
DEC / 13 |
Pheniramine |
|
U |
|
Phenmetrazine and any salt thereofC |
|
I |
JUN / 02 |
Phenol |
preparations with concentration of more than 20% |
II |
SEP / 98 |
Phenoxybenzamine and its salts |
|
II |
SEP / 98 |
Phentermine and any salt thereofC |
|
I |
JUN / 02 |
Phenthoxate or its salts |
|
I |
DEC / 13 |
Phentolamine or its salts |
|
I |
DEC / 13 |
Phenylbutazone or its salts |
|
I |
DEC / 13 |
Phenylbutyric acid or its salts or derivatives |
Including but not limited to glycerol phenylbutyrate, phenylbutyrate sodium.
|
I |
AUG / 16 |
Phenylephrine and its salts and preparations |
in nasal preparations in concentrations of 2.5% or less, for pediatric use |
II |
SEP / 98 |
Phenylephrine and its salts and preparations. |
for oral use, in nasal preparations for adults and in ophthalmic preparations in concentrations of 2.5% or less |
U |
|
Phenylephrine or its salts |
In preparations for parenteral use or ophthalmic use in concentrations greater than 2.5%.
|
I |
DEC / 13 |
Phenylindanedione or its derivatives |
|
I |
DEC / 13 |
Phenylpiperidines, their intermediates, salts, derivatives and analogues and salts of intermediates, derivatives and analoguesN |
Including: Allylprodine; Alphameprodine; Alphaprodine; Anileridine; Betameprodine; Betaprodine; Benzethidine; Diphenoxylate; Difenoxin; Etoxeridine; Furethidine; Hydroxypethidine; Ketobemidone; Methylphenylisonipecotonitrile; Morpheridine; Norpethidine; Pethidine; Phenoperidine; Piminodine; Properidine; Trimeperidine; Pethidine Intermediate C; but not including: Carperidine and its salts; Oxpheneridine and its salts
|
I |
JUN / 02 |
Phenylpropanolamine or its salts or derivatives |
|
I |
DEC / 13 |
Phenyltoloxamine and its salts |
|
III |
SEP / 98 |
Physostigmine salicylate |
For human use - except preparations for oral or topical use only.
|
I |
DEC / 13 |
Physostigmine salicylate. |
for oral or topical use
|
II |
SEP / 98 |
Phytocannabinoids produced by, or found in, the cannabis plant and substances that are duplicates of such phytocannabinoids.* |
except:
1) derivatives of cannabis as defined in subsection 2(1) of the Cannabis Act that are exempt from the application of the Cannabis Act under the Industrial Hemp Regulations and that do not contain an isolated or concentrated phytocannabinoid or a synthetic duplicate of that phytocannabinoid, or
2) anything referred to in Schedule 2 to the Cannabis Act that contains no more than 10 µg/g delta-9-tetrahydrocannabinol and that does not contain an isolated or concentrated phytocannabinoid or a synthetic duplicate of that phytocannabinoid.
*Note: this listing is copied from the Health Canada Prescription Drug List and applies to products that have received a Notice of Compliance and Drug Identification Number and been classified as prescription drugs by Health Canada. Cannabis products, as defined in the Cannabis Act and its regulations, are not granted a Notice of Compliance and Drug Identification Number by Health Canada and are considered outside the scope of the National Drug Schedules.
|
I |
OCT / 18 |
Pibrentasvir |
|
I |
SEP / 17 |
Pilocarpine or its salts |
|
I |
DEC / 13 |
Pimecrolimus |
|
I |
DEC / 13 |
Pimobendan |
|
I |
DEC / 13 |
Pimozide |
|
I |
DEC / 13 |
Pinaverium bromide |
|
I |
DEC / 13 |
Pindolol or its salts |
|
I |
DEC / 13 |
Pioglitazone or its salts |
|
I |
DEC / 13 |
Pipecuronium bromide |
|
I |
DEC / 13 |
Piperacetazine or its salts |
|
I |
DEC / 13 |
Piperazine and its salts |
|
II |
SEP / 98 |
Piperilate or its salts |
|
I |
DEC / 13 |
Pipobroman |
|
I |
DEC / 13 |
Pipotiazine or its salts |
|
I |
DEC / 13 |
Pipradrol and any salt thereofTS |
|
I |
SEP / 98 |
Pirbuterol or its salts |
|
I |
DEC / 13 |
Pirenzepine or its salts |
|
I |
DEC / 13 |
Pirfenidone or its derivatives |
|
I |
DEC / 13 |
Pirlimycin or its salts |
|
I |
DEC / 13 |
Piroxicam or its salts |
|
I |
DEC / 13 |
Pizotyline or its salts |
|
I |
DEC / 13 |
Plecanatide |
|
I |
NOV / 19 |
Plerixafor or its salts |
|
I |
DEC / 13 |
Pneumococcal 7-valent conjugate vaccine |
|
II |
JAN / 04 |
Pneumococcal polysaccharide vaccines |
|
II |
FEB / 02 |
Podophyllotoxin |
When recommended for topical use.
|
I |
DEC / 13 |
Polatuzumab vedotin |
|
I |
SEP / 20 |
Polidocanol |
When indicated for administration by injection.
|
I |
JAN / 16 |
Poliomyelitis vaccine |
|
II |
DEC / 98 |
Polyacrylamide |
|
II |
SEP / 98 |
Polyethylene glycol |
topical administration |
U |
|
Polyethylene glycol 3350 |
as a single ingredient oral product indicated as a laxative to treat occasional constipation |
U |
JUL / 10 |
Polymyxin B or its salts or derivatives |
For human use - except for topical use or for local action in the oral cavity or nasal passages.
|
I |
DEC / 13 |
Polymyxin B or its salts or derivatives. |
For veterinary use - when sold in combination with other medicinal ingredients.
|
I |
APR / 16 |
Polymyxin B or its salts or derivatives.. |
for human, ophthalmic use
|
III |
JUN / 06 |
Polymyxin or its salts or derivatives |
for human, topical use |
U |
|
Polysulfated glycosaminoglycan |
|
I |
DEC / 13 |
Pomalidomide or its salts |
|
I |
FEB / 14 |
Ponatinib or its salts |
|
I |
MAY / 15 |
Poractant alfa |
|
I |
DEC / 13 |
Porfimer or its salts |
|
I |
DEC / 13 |
Posaconazole |
|
I |
DEC / 13 |
Potassium bromide |
|
I |
DEC / 13 |
Potassium citrate |
When recommended for the treatment of renal tubular acidosis and kidney stones.
|
I |
DEC / 13 |
Potassium gluconate |
For veterinary use - when sold or recommended for administration to cats.
|
I |
DEC / 13 |
Potassium para-aminobenzoate |
Except in preparations for topical use on the skin.
|
I |
DEC / 13 |
Potassium salts |
In preparations for injection.
|
I |
DEC / 99 |
Potassium salts. |
in oral preparations containing more than 5 mmol per single dose [except potassium bromide, potassium gluconate when sold or recommended for administration to cats, potassium para-aminobenzoate, potassium citrate when recommended for the treatment of renal tubular acidosis and kidney stones] |
II |
DEC / 13 |
Povidone - iodine |
vaginal preparations, except in concentrations of 5% or less |
II |
SEP / 98 |
Pradofloxacin or their salts or derivatives |
|
I |
MAR / 15 |
Pralatrexate or its salts |
|
I |
DEC / 18 |
Pralidoxime or its salts |
|
I |
DEC / 13 |
Pramipexole or its salts |
|
I |
DEC / 13 |
Pramoxine and its salts |
for ophthalmic or parenteral use |
II |
SEP / 98 |
Pramoxine and its salts. |
for topical use on mucous membranes, except lozenges
|
III |
SEP / 98 |
Pramoxine and its salts.. |
for topical application on the skin, and including lozenges |
U |
DEC / 05 |
Prasugrel or its salts |
|
I |
DEC / 13 |
Pravastatin or its salts |
|
I |
DEC / 13 |
Praziquantel |
For human use.
|
I |
DEC / 13 |
Praziquantel |
For veterinary use - except when sold for the treatment of the tapeworm Anoplocephala perfoliata in horses.
|
I |
DEC / 13 |
Prazosin or its salts |
|
I |
DEC / 13 |
Pregabalin or its salts or derivatives |
|
I |
DEC / 13 |
Prenylamine or its salts |
|
I |
DEC / 13 |
Prilocaine and its salts |
for ophthalmic or parenteral use
|
II |
SEP / 98 |
Prilocaine and its salts. |
for topical use on mucous membranes, except lozenges
|
III |
SEP / 98 |
Primaquine or its salts |
|
I |
DEC / 13 |
Primidone |
For human use.
|
I |
DEC / 13 |
Probenecid or its salts |
|
I |
DEC / 13 |
Probucol |
|
I |
DEC / 13 |
Procainamide or its salts |
|
I |
DEC / 13 |
Procaine and its salts |
for topical use on mucous membranes, except lozenges |
III |
SEP / 98 |
Procaine and its salts |
for ophthalmic or parenteral use |
II |
SEP / 98 |
Procarbazine or its salts |
|
I |
DEC / 13 |
Procaterol or its salts |
|
I |
DEC / 13 |
Prochlorperazine or its salts |
|
I |
DEC / 13 |
Procyclidine or its salts |
|
I |
DEC / 13 |
Prodilidine or its salts |
|
I |
DEC / 13 |
Profenamine or its salts |
Including but not limited to ethopropazine.
|
I |
DEC / 13 |
Progesterone or its derivatives |
For veterinary use - except when recommended for use in progesterone implants indicated for growth promotion, melengestrol acetate in feed for the suppression of estrus in beef heifers.
|
I |
DEC / 13 |
Proguanil or its salts |
|
I |
DEC / 13 |
Promazine or its salts |
For human use.
|
I |
DEC / 13 |
Promethazine and its salts |
except for topical use |
II |
SEP / 98 |
Promethazine and its salts |
for topical use |
III |
SEP / 98 |
Propafenone or its salts |
|
I |
DEC / 13 |
Propantheline and its salts |
|
II |
SEP / 98 |
Proparacaine and its salts |
for ophthalmic or parenteral use |
II |
SEP / 98 |
Proparacaine and its salts |
for topical use on mucous membranes, except lozenges |
III |
SEP / 98 |
Propiverine or its salts |
|
I |
MAR / 17 |
Propofol |
|
I |
DEC / 13 |
Propranolol or its salts |
|
I |
DEC / 13 |
Propylene glycol |
topical application |
U |
|
Propylhexedrine |
|
II |
SEP / 98 |
Proquamezine [aminopromazine] and its salts |
For internal use.
|
I |
SEP / 98 |
Prostaglandins or their salts or derivatives or analogues |
Including but not limited to: Alprostadil, bimatoprost, cloprostenol, dinoprostone, epoprostenol, fluprostenol, latanoprost, latanoprostene bunod, lubiprostone, misoprostol, tafluprost, travoprost, treprostinil, unoprostone.
|
I |
AUG / 15 |
Protamine and its salts |
|
II |
SEP / 98 |
Prothipendyl hydrochloride |
|
I |
DEC / 13 |
Protirelin |
|
I |
DEC / 13 |
Protriptyline or its salts |
|
I |
DEC / 13 |
Prucalopride or its salts |
Including but not limited to prucalopride succinate.
|
I |
DEC / 13 |
Pseudoephedrine and its salts and preparations in combination products |
Note: Pharmacists are advised that in areas where there is evidence of abuse or particular concern about abuse, pseudoephedrine products should not be located in a self-selection area of the pharmacy |
III |
APR / 06 |
Pseudoephedrine and its salts and preparations in single entity products |
|
II |
APR / 06 |
Pyrantel and its salts |
|
II |
SEP / 98 |
Pyrazinamide |
|
I |
DEC / 13 |
Pyrethrins |
|
II |
SEP / 98 |
Pyrethrins/piperonyl butoxide |
|
II |
SEP / 98 |
Pyridostigmine bromide |
|
I |
DEC / 13 |
Pyrilamine |
|
U |
|
Pyrimethamine or its salts |
|
I |
DEC / 13 |
Pyrovalerone and any salt thereofC |
|
I |
JAN / 03 |
Pyrvinium and its salts |
|
II |
SEP / 98 |
Quetiapine or its salts |
|
I |
DEC / 13 |
Quinagolide or its salts |
|
I |
DEC / 13 |
Quinapril or its salts or derivatives |
|
I |
DEC / 13 |
Quinidine salts |
|
I |
SEP / 98 |
Quinine or its salts or derivatives |
Except when sold in oral dosage form that provides 50 mg or less of quinine base per dosage unit or per daily dose.
|
I |
DEC / 13 |
Quinupristin or its salts |
|
I |
DEC / 13 |
Rabeprazole or its salts |
|
I |
DEC / 13 |
Rabies immune globulin |
|
I |
FEB / 02 |
Rabies vaccine |
|
I |
FEB / 02 |
Racemethionine |
|
II |
SEP / 98 |
Raloxifene or its salts |
|
I |
DEC / 13 |
Raltegravir or its salts |
|
I |
DEC / 13 |
Raltitrexed or its salts or derivatives |
Including but not limited to raltitrexed disodium.
|
I |
DEC / 13 |
Ramipril or its salts or derivatives |
|
I |
DEC / 13 |
Ramucirumab |
|
I |
OCT / 15 |
Ranibizumab |
|
I |
DEC / 13 |
Ranitidine or its salts |
For human use - except when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn.
|
I |
DEC / 13 |
Ranitidine or its salts. |
when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing more than 4,500 mg of ranitidine |
III |
MAR / 08 |
Ranitidine or its salts.. |
when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing no more than 4,500 mg of ranitidine |
U |
FEB / 07 |
Rasagiline or its salts |
|
I |
DEC / 13 |
Rasburicase |
|
I |
DEC / 13 |
Raubasine or its salts |
|
I |
DEC / 13 |
Rauwolfia |
|
I |
DEC / 13 |
Ravulizumab |
|
I |
OCT / 19 |
Regorafenib or its salts |
|
I |
DEC / 13 |
Remdesivir or its salts or derivatives |
|
I |
JUL / 20 |
Remestemcel-L |
|
I |
DEC / 13 |
Remoxipride or its salts |
|
I |
DEC / 13 |
Repaglinide or its salts or derivatives |
|
I |
DEC / 13 |
Rescinnamine or its salts |
|
I |
DEC / 13 |
Reserpine or its salts |
For human use.
|
I |
DEC / 13 |
Reslizumab |
|
I |
JUN / 17 |
Resocortol or its derivativesPDL |
|
I |
DEC / 13 |
Retapamulin |
|
I |
DEC / 13 |
Reviparin or its salts |
|
I |
DEC / 13 |
Rho D immune globulin |
|
I |
FEB / 02 |
Ribavirin |
|
I |
DEC / 13 |
Ribociclib or its salts |
|
I |
MAY / 18 |
Rifabutin or its salts |
|
I |
DEC / 13 |
Rifampin or its salts or derivatives |
|
I |
DEC / 13 |
Rifaximin or its salts or derivatives |
|
I |
DEC / 13 |
Rilpivirine or its salts or derivatives |
Including but not limited to rilpivirine hydrochloride.
|
I |
DEC / 13 |
Riluzole or its salts |
|
I |
DEC / 13 |
Riociguat or its derivatives |
|
I |
DEC / 13 |
Ripretinib or its salts |
|
I |
SEP / 20 |
Risankizumab |
|
I |
JUL / 19 |
Risedronic acid or its salts |
|
I |
DEC / 13 |
Risperidone or its salts |
|
I |
DEC / 13 |
Ritodrine and its salts |
|
I |
DEC / 13 |
Ritonavir |
|
I |
DEC / 13 |
Rituximab |
|
I |
DEC / 13 |
Rivaroxaban |
|
I |
DEC / 13 |
Rivastigmine or its salts |
|
I |
DEC / 13 |
Rizatriptan or its salts |
|
I |
DEC / 13 |
Robenacoxib or its salts |
|
I |
DEC / 13 |
Rocuronium bromide |
|
I |
DEC / 13 |
Rofecoxib |
|
I |
DEC / 13 |
Roflumilast or its salts or derivatives |
|
I |
DEC / 13 |
Romidepsin |
|
I |
DEC / 13 |
Romifidine or its salts |
|
I |
DEC / 13 |
Romiplostim |
|
I |
DEC / 13 |
Romosozumab |
|
I |
OCT / 19 |
Ronidazole or its salts or derivatives |
For human use.
|
I |
DEC / 13 |
Ropinirole or its salts |
|
I |
DEC / 13 |
Rose Bengal |
|
II |
SEP / 98 |
Rosiglitazone or its salts |
|
I |
DEC / 13 |
Rosoxacin or its salts |
|
I |
DEC / 13 |
Rosuvastatin or its salts |
|
I |
DEC / 13 |
Rotigotine or its salts or derivatives |
|
I |
DEC / 13 |
Rubella vaccine |
|
II |
DEC / 98 |
Rue and its preparations and extracts |
|
II |
SEP / 98 |
Rufinamide or its derivatives |
|
I |
DEC / 13 |
Rupatadine or its salts |
|
I |
FEB / 17 |
Ruxolitinib or its salts |
Including but not limited to ruxolitinib phosphate.
|
I |
DEC / 13 |
Sacubitril or its salts |
|
I |
JAN / 16 |
Safinamide or its salts |
|
I |
FEB / 19 |
Salbutamol or its salts |
|
I |
DEC / 13 |
Salicylic acid |
When sold in topical formulations containing salicylic acid at concentrations greater than 20% and/or with a pH less than 3.0, except when sold to be applied to warts, corns or calluses.
|
I |
DEC / 14 |
Salicylic acid and its salts |
when sold to be applied to warts, corns or calluses in topical preparations in concentrations greater than 40% |
II |
DEC / 14 |
Salmeterol or its salts |
|
I |
DEC / 13 |
Salsalate or its salts or derivatives |
|
I |
DEC / 13 |
Sapropterin or its salts |
|
I |
DEC / 13 |
Saquinavir or its salts or derivatives |
|
I |
DEC / 13 |
Saralasin or its salts |
|
I |
DEC / 13 |
Sargramostim |
|
I |
DEC / 13 |
Sarilumab |
|
I |
MAR / 17 |
Sarolaner |
For veterinary use.
|
I |
AUG / 16 |
Satralizumab |
|
I |
SEP / 20 |
Saxagliptin or its salts |
|
I |
DEC / 13 |
Sebelipase alfa |
|
I |
MAR / 18 |
SecobarbitalC |
|
I |
JUN / 02 |
Secukinumab |
|
I |
MAY / 15 |
Selegiline or its salts |
|
I |
DEC / 13 |
Selenium in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Selexipag or its derivatives |
|
I |
AUG / 16 |
Semaglutide |
|
I |
MAR / 18 |
Sermorelin or its salts |
|
I |
DEC / 13 |
Sertraline or its salts |
|
I |
DEC / 13 |
Sevelamer or its salts |
|
I |
DEC / 13 |
Sevoflurane |
|
I |
DEC / 13 |
Sex hormones (natural or synthetic) |
For human use - including but not limited to conjugated estrogens, desogestrel, dienogest, estradiol benzoate, estradiol(hemihydrate), estrone, ethinyl estradiol, ethynodiol diacetate, etonogestrel, levonorgestrel, medroxyprogesterone acetate, norelgestromin, norethindrone acetate, norgestimate, progesterone except the following: androisoxazole, androstanolone, androstenediol or its derivatives, bolandiol or its derivatives, bolasterone, bolazine, boldenone or its derivatives, bolenol, calusterone, clostebol or its derivatives, drostanolone or its derivatives, enestebol, epitiostanol, ethylestrenol, fluoxymesterone, formebolone, furazabol, 4-Hydroxy-19-nortestosterone or its derivatives, levonorgestrel when sold as a single ingredient in an oral dosage form containing no more than 1.5 milligrams, mebolazine,mesabolone, mesterolone, metandienone, metenolone or its derivatives, methandriol, methyltestosterone or its derivatives, metribolone, mibolerone, nandrolone or its derivatives, norboletone, norclostebol or its derivatives, norethandrolone, oxabolone or its derivatives, oxandrolone, oxymesterone, oxymetholone, prasterone, quinbolone, stanozolol, stenbolone or its derivatives, testosterone or its derivatives, tibolone, tiomesterone, trenbolone or its derivatives, zeranol.
|
I |
AUG / 15 |
Sibutramine or its salts |
|
I |
DEC / 13 |
Sildenafil or its salts |
|
I |
DEC / 13 |
Silodosin or its salts or derivatives |
|
I |
DEC / 13 |
Siltuximab |
|
I |
DEC / 14 |
Silver nitrate |
|
II |
SEP / 98 |
Simeprevir or its salts |
|
I |
DEC / 13 |
Simvastatin |
|
I |
DEC / 13 |
Sincalide |
|
II |
SEP / 98 |
Siponimod or its salts |
|
I |
JUL / 20 |
Sirolimus or its derivatives |
Including but not limited to everolimus, temsirolimus.
|
I |
DEC / 13 |
Sitagliptin or its salts |
|
I |
DEC / 13 |
Sitaxentan or its salts |
|
I |
DEC / 13 |
Sodium Zirconium cyclosilicate |
|
I |
OCT / 19 |
Sodium acetate |
for parenteral use |
II |
SEP / 98 |
Sodium acetate in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Sodium biphosphate |
for parenteral use
|
II |
SEP / 98 |
Sodium bromide |
|
I |
DEC / 13 |
Sodium chloride |
single ingredient solutions for parenteral or ophthalmic use in concentrations of more than 0.9% [NOTE: Does not apply to contact lens solutions intended to be rinsed off prior to insertion into eye] |
II |
OCT / 98 |
Sodium chloride in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Sodium citrate |
for parenteral use |
II |
SEP / 98 |
Sodium cromoglicate (cromoglycate) |
in solutions in concentrations of 2% or less for ophthalmic or nasal use |
III |
SEP / 98 |
Sodium fluoride (see Fluoride) |
For human use - in solid oral dosage forms containing more than 1 mg of fluoride ion.
|
I |
DEC / 13 |
Sodium iodide |
for sclerosing |
II |
SEP / 98 |
Sodium iodine in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Sodium nitrite |
When indicated for administration by injection and sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning.
|
I |
JUN / 15 |
Sodium nitroprusside or its salts |
|
I |
DEC / 13 |
Sodium phosphate |
for parenteral use |
II |
SEP / 98 |
Sodium phosphate in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Sodium picosulphate |
for oral purgatives, 10 mg per pack (when found in preparations with magnesium oxide 3.5 g and citric acid 12 g)
|
II |
JAN / 10 |
Sodium polystyrene sulfonate |
|
I |
DEC / 13 |
Sodium tetradecylsulfate |
|
II |
SEP / 98 |
Sofosbuvir or its salts |
|
I |
FEB / 14 |
Solifenacin or its salts |
|
I |
DEC / 13 |
Somatostatin |
|
I |
DEC / 13 |
Somatrem |
|
I |
DEC / 13 |
Somatropin |
|
I |
DEC / 13 |
Sonidegib or its salts |
|
I |
SEP / 20 |
Sorafenib or its salts |
|
I |
DEC / 13 |
Sotalol or its salts |
|
I |
DEC / 13 |
Spectinomycin or its salts or derivatives |
|
I |
DEC / 18 |
Spinosyn A and D isoforms |
|
I |
DEC / 13 |
Spiramycin or its salts or derivatives |
For human use.
|
I |
DEC / 13 |
Spironolactone |
|
I |
DEC / 13 |
Stavudine |
|
I |
DEC / 13 |
Stiripentol |
|
I |
DEC / 13 |
Stramonium, its preparations, extracts and compounds |
|
II |
SEP / 98 |
Streptokinase |
as a debriding agent |
II |
SEP / 98 |
Streptokinase/streptodornase |
|
I |
SEP / 98 |
Streptomycin or its salts or derivatives |
For human use
|
I |
DEC / 18 |
Streptomycin or its salts or derivatives |
For veterinary use, including but not limited to dihydrostreptomycin
|
I |
DEC / 18 |
Streptozocin |
|
I |
DEC / 13 |
Strontium and its salts |
for parenteral use |
II |
SEP / 98 |
Strontium bromide |
|
I |
DEC / 13 |
Succinimide or its salts or derivatives |
Including but not limited to methsuximide, except those compounds used for decontaminating water.
|
I |
DEC / 13 |
Succinylcholine and its salts |
|
I |
SEP / 98 |
Sucralfate |
|
I |
SEP / 98 |
Sucroferric oxyhydroxide |
|
I |
MAY / 18 |
Sugammadex or its salts |
|
I |
AUG / 16 |
Sulconazole or its salts |
|
I |
DEC / 13 |
Sulfinpyrazone or its salts |
|
I |
DEC / 13 |
Sulindac or its salts |
|
I |
DEC / 13 |
Sulphonamides or their salts or derivatives |
Including but not limited to Brinzolamide, succinylsulfathiazole, sulfacetamide, sulfadiazine, sulfadimethoxine, sulfadoxine, sulfaguanidine, sulfamerazine, sulfamethazine, sulfamethoxazole, sulfanilamide, sulfapyridine, sulfaquinoxaline, sulfasalazine, sulfathiazole, sulfisoxazole, sulphanilamide
|
I |
DEC / 18 |
Sulphones or their derivatives |
Including but not limited to dapsone.
|
I |
DEC / 13 |
Sumatriptan or its salts |
|
I |
DEC / 13 |
Sunitinib or its salts |
|
I |
DEC / 13 |
Suprofen or its salts |
|
I |
DEC / 13 |
Sutilains |
|
II |
SEP / 98 |
Suvorexant |
|
I |
DEC / 18 |
Suxamethonium chloride |
|
I |
DEC / 13 |
Synthetic cannabinoid receptor type-1 agonists, their salts, derivatives, isomers, and salts of derivatives and isomers N |
as listed in the schedule to the Narcotic Control Regulations under the Controlled Drugs and Substances Act
(Note: includes nabilone)
|
I |
JUL / 15 |
Tacrolimus or its derivatives |
|
I |
DEC / 13 |
Tadalafil or its salts |
|
I |
DEC / 13 |
Tafamidis or its salts |
|
I |
FEB / 20 |
Talazoparib or its salts |
|
I |
NOV / 19 |
Taliglucerase alfa |
|
I |
JUN / 14 |
Tamoxifen or its salts |
|
I |
DEC / 13 |
Tamsulosin or its salts |
|
I |
DEC / 13 |
Tapentadol, its salts, derivatives and isomers and salts of derivatives and isomersN |
|
I |
JAN / 16 |
Tazarotene |
|
I |
DEC / 13 |
Tazobactam or its salts or derivatives |
|
I |
DEC / 13 |
Tedizolid or its salts or derivatives |
Including but not limited to Tedizolid phosphate.
|
I |
MAY / 15 |
Teduglutide |
|
I |
OCT / 15 |
Teflubenzuron |
|
I |
DEC / 13 |
Tegaserod or its salts |
|
I |
DEC / 13 |
Telaprevir or its derivatives |
|
I |
DEC / 13 |
Telbivudine |
|
I |
DEC / 13 |
Telmisartan or its salts or derivatives |
|
I |
DEC / 13 |
Telotristat or its salts or derivatives |
|
I |
NOV / 18 |
Temozolomide or its salts |
|
I |
DEC / 13 |
Tenapanor or its salts |
|
I |
JUL / 20 |
Teniposide |
|
I |
DEC / 13 |
Tenofovir or its salts or derivatives |
Including but not limited to: tenofovir disoproxil, tenofovir alafenamide
|
I |
DEC / 13 |
Tenoxicam or its salts |
|
I |
DEC / 13 |
Tepoxalin or its derivatives |
|
I |
DEC / 13 |
Terazosin or its salts |
|
I |
DEC / 13 |
Terbinafine or its salts |
|
I |
DEC / 13 |
Terbutaline or its salts |
|
I |
DEC / 13 |
Terconazole or its salts |
|
I |
DEC / 13 |
Terfenadine or its salts |
|
I |
DEC / 13 |
Teriparatide or its salts |
|
I |
DEC / 13 |
Terlipressin or its salts |
|
I |
DEC / 13 |
Tesamorelin or its salts or derivatives |
|
I |
APR / 14 |
Tetanus immune globulin |
|
I |
FEB / 02 |
Tetanus toxoid |
|
II |
DEC / 98 |
Tetrabenazine or its salts |
|
I |
DEC / 13 |
Tetracaine |
when in a preparation containing an equal amount of lidocaine and recommended for topical use on the skin, in concentrations of 7% or higher
|
I |
FEB / 14 |
Tetracaine and its salts |
for ophthalmic or parenteral use
|
II |
SEP / 98 |
Tetracaine and its salts |
for topical use on mucous membranes, except lozenges |
III |
SEP / 98 |
Tetracosactide or its salts |
For veterinary use
|
I |
JUL / 20 |
Tetracycline or its salts or derivatives |
|
I |
DEC / 18 |
Tetrahydrozoline |
in nasal preparations for pediatric use |
II |
SEP / 98 |
Tetrahydrozoline. |
for ophthalmic use and in nasal preparations for adults |
U |
|
Tezacaftor or its salts |
|
I |
JUL / 18 |
Thalidomide |
|
I |
DEC / 13 |
Theophylline or its salts |
|
I |
DEC / 13 |
Thiabendazole |
For human use
|
I |
DEC / 13 |
Thiambutenes, their salts, derivatives and salts of derivativesN |
Including: Diethylthiambutene, Dimethylthiambutene, Ethylmethylthiambutene
|
I |
JUN / 02 |
Thiethylperazine or its salts |
|
I |
DEC / 13 |
Thiobarbiturates, their salts and derivativesC |
Including: Thialbarbital; Thiamylal; Thiobarbituric Acid; Thiopental
|
I |
JUN / 02 |
Thiocarlide |
|
I |
DEC / 13 |
Thioguanine |
|
I |
DEC / 13 |
Thiopropazate or its salts |
|
I |
DEC / 13 |
Thioproperazine or its salts |
|
I |
DEC / 13 |
Thioridazine or its salts |
|
I |
DEC / 13 |
Thiotepa |
|
I |
DEC / 13 |
Thiothixene or its salts |
|
I |
DEC / 13 |
Thiouracil or its derivatives |
|
I |
DEC / 13 |
Thrombin |
|
II |
SEP / 98 |
Thyroglobulin |
|
II |
SEP / 98 |
Thyroid |
For human use
|
I |
DEC / 13 |
Thyrotropin |
|
II |
SEP / 98 |
Thyrotropin alfa |
|
I |
DEC / 13 |
Thyroxin or its salts |
Including but not limited to Levothyroxine sodium
|
I |
DEC / 13 |
Tiamulin or its salts |
For veterinary use, including but not limited to: Tiamulin fumarate
|
I |
DEC / 18 |
Tiaprofenic acid or its salts |
|
I |
DEC / 13 |
Ticagrelor or its derivatives |
|
I |
DEC / 13 |
Ticarcillin or its salts or derivatives |
For veterinary use
|
I |
DEC / 13 |
Ticlopidine or its salts |
|
I |
DEC / 13 |
Tigecycline |
|
I |
DEC / 13 |
Tilidine and its salts, derivatives and salts of derivativesN |
|
I |
JUN / 02 |
Tiludronic acid or its salts |
|
I |
DEC / 13 |
Timolol or its salts |
|
I |
DEC / 13 |
Tinidazole |
|
I |
DEC / 13 |
Tinzaparin or its salts |
|
I |
DEC / 13 |
Tioconazole and its salts.. |
in preparations for intra-vaginal use |
III |
OCT / 98 |
Tioconazole and its salts... |
in preparations for topical use |
U |
OCT / 98 |
Tioconazole or its salts |
For human use, except in preparations for topical or vaginal use
|
I |
DEC / 13 |
Tiotropium bromide |
|
I |
DEC / 13 |
Tipiracil or its salts |
|
I |
MAR / 18 |
Tipranavir or its salts |
|
I |
DEC / 13 |
Tirofiban or its salts or derivatives |
|
I |
DEC / 13 |
Tisagenlecleucel |
|
I |
OCT / 18 |
Tizanidine or its salts |
|
I |
DEC / 13 |
Tobramycin or its salts or derivatives |
|
I |
DEC / 13 |
Tocainide or its salts |
|
I |
DEC / 13 |
Toceranib or its salts |
|
I |
DEC / 13 |
Tocilizumab |
|
I |
DEC / 13 |
Tofacitinib or its salts |
|
I |
APR / 14 |
Tolazamide |
|
I |
DEC / 13 |
Tolazoline or its salts |
|
I |
DEC / 13 |
Tolbutamide |
|
I |
DEC / 13 |
Tolcapone |
|
I |
DEC / 13 |
Tolfenamic acid or its salts or derivatives |
|
I |
DEC / 13 |
Tolmetin or its salts |
|
I |
DEC / 13 |
Tolterodine or its salts |
|
I |
DEC / 13 |
Toltrazuril or its salts or derivatives |
Including but not limited to Ponazuril
|
I |
DEC / 13 |
Tolvaptan or its derivatives |
|
I |
DEC / 13 |
Topiramate |
|
I |
DEC / 13 |
Topotecan or its salts |
|
I |
DEC / 13 |
Torasemide or its salts |
|
I |
DEC / 13 |
Toremifene or its salts |
|
I |
DEC / 13 |
Trabectedin or its salts or derivatives |
|
I |
DEC / 13 |
Tramadol or its salts |
|
I |
DEC / 13 |
Trametinib or its salts or derivatives |
Including but not limited to Trametinib dimethylsulfoxide.
|
I |
DEC / 13 |
Trandolapril or its salts or derivatives |
|
I |
DEC / 13 |
Tranexamic acid |
|
I |
DEC / 13 |
Tranylcypromine |
|
I |
DEC / 13 |
Trastuzumab |
|
I |
DEC / 13 |
Trastuzumab emtansine |
|
I |
DEC / 13 |
Trazodone or its salts |
|
I |
DEC / 13 |
Treosulfan |
|
I |
DEC / 13 |
Tretamine |
|
I |
DEC / 13 |
Tretinoin or its salts or derivatives |
|
I |
DEC / 13 |
Triamcinolone acetonide |
in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older, in package sizes containing more than 120 metered sprays
|
II |
JAN / 15 |
Triamcinolone acetonide. |
in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older, in package sizes containing no more than 120 metered sprays
|
III |
JAN / 15 |
Triamterene or its salts |
|
I |
DEC / 13 |
Tricaine or its salts |
|
I |
DEC / 13 |
Trientine or its saltsPDL |
|
I |
DEC / 20 |
Triethanolamine oleate |
|
III |
SEP / 98 |
Triethanolamine salicylate |
in concentrations greater than 20% |
III |
SEP / 98 |
Triethanolamine salicylate. |
in concentrations up to and including 20% |
U |
|
Trifarotene or its salts |
|
I |
FEB / 20 |
Trifluoperazine or its salts |
|
I |
DEC / 13 |
Triflupromazine or its salts |
|
I |
DEC / 13 |
Trifluridine |
|
I |
DEC / 13 |
Trihexyphenidyl or its salts |
|
I |
DEC / 13 |
Triiodothyropropionic acid |
|
I |
DEC / 13 |
Trilostane |
|
I |
DEC / 13 |
Trimebutine or its salts |
|
I |
DEC / 13 |
Trimeprazine or its salts |
For human use.
|
I |
DEC / 13 |
Trimethadione |
|
I |
DEC / 13 |
Trimethaphan camsylate |
|
I |
DEC / 13 |
Trimethoprim or its salts |
|
I |
DEC / 13 |
Trimetrexate or its salts |
|
I |
DEC / 13 |
Trimipramine or its salts |
|
I |
DEC / 13 |
Trioxsalen |
|
I |
DEC / 13 |
Tripelennamine and its salts |
|
III |
SEP / 98 |
Triprolidine |
|
III |
SEP / 98 |
Triptorelin or its salts or derivatives |
|
I |
DEC / 13 |
Troglitazone |
|
I |
DEC / 13 |
Tropicamide or its salts |
For human use - in preparations for parenteral or ophthalmic use, except when sold for use in diagnostic procedures to an optometrist registered in a province of Canada.
|
I |
DEC / 13 |
Tropicamide or its salts |
For veterinary use.
|
I |
DEC / 13 |
Trospium chloride |
|
I |
DEC / 13 |
Trovafloxacin or its salts or derivatives |
including but not limited to alatrofloxacin
|
I |
DEC / 13 |
Tubocurarine chloride |
|
I |
DEC / 13 |
Tucatinib or its salts or derivatives |
|
I |
JUL / 20 |
Tulathromycin |
For veterinary use.
|
I |
DEC / 13 |
Tybamate |
|
I |
DEC / 13 |
Tylosin or its salts or derivatives |
Including but not limited to: Tildipirosin, tilmicosin, tylvalosin.
|
I |
DEC / 18 |
Typhoid vaccines/Salmonella Typhi vaccines |
|
I |
FEB / 02 |
Tyrothricine |
|
III |
SEP / 98 |
Ulipristal or its salts or derivatives |
Including but not limited to Ulipristal acetate.
|
I |
DEC / 13 |
Umeclidinium or its salts or derivatives |
|
I |
FEB / 14 |
Upadacitinib or its salts |
|
I |
FEB / 20 |
Uracil and its salts |
When sold for the treatment of cancer.
|
I |
DEC / 13 |
Uracil mustard or its salts |
|
I |
DEC / 13 |
Urea |
in topical preparations in concentrations of more than 25% |
II |
SEP / 98 |
Urokinase |
|
I |
DEC / 13 |
Ursodeoxycholic acid or its salts |
|
I |
DEC / 13 |
Ustekinumab |
|
I |
DEC / 13 |
Vaccines |
(except for - those which are part of a routine immunization program in most/all provinces and territories: Diphtheria toxoid, Tetanus toxoid, Pertussis, Poliomyelitis, Haemophilus influenza type B, Measles, Mumps, Pneumococcus, Rubella, Hepatitis B Pediatric, Influenza, cholera vaccine (oral, inactivated) when used for prophylaxis against traveller's diarrhea & due to enterotoxigenic escherichia coli (ETEC); and those requiring special enhanced public access due to disease outbreaks: Meningococcus) |
I |
FEB / 02 |
Vaccines. |
which are part of a routine immunization program in most/all provinces and territories: Diptheria toxoid, Tetanus toxoid, Pertussis, Poliomyelitis, Haemophilus influenza type B, Measles, Mumps, Pneumococcus, Rubella, Hepatitis B Pediatric, Influenza, cholera vaccine (oral, inactivated) when used for prophylaxis against traveller's diarrhea & due to enterotoxigenic escherichia coli (ETEC); and those requiring special enhanced public access due to disease outbreaks: Meningococcus |
II |
FEB / 02 |
Valaciclovir or its salts |
|
I |
DEC / 13 |
Valdecoxib or its salts |
|
I |
DEC / 13 |
Valganciclovir or its salts or derivatives |
|
I |
DEC / 13 |
Valproic acid or its salts |
Including but not limited to Divalproex sodium
|
I |
DEC / 13 |
Valrubicin or its derivatives |
|
I |
DEC / 13 |
Valsartan or its salts or derivatives |
|
I |
DEC / 13 |
Vancomycin or its salts or derivatives |
Including but not limited to Telavancin.
|
I |
DEC / 13 |
Vandetanib or its salts or derivatives |
|
I |
DEC / 13 |
Vardenafil or its salts |
|
I |
DEC / 13 |
Varenicline or its salts |
|
I |
DEC / 13 |
Varicella Zoster immune globulin |
|
I |
FEB / 02 |
Varicella vaccine (chicken pox) |
|
I |
FEB / 02 |
Vasopressin or its salts |
|
I |
DEC / 13 |
Vecuronium bromide |
|
I |
DEC / 13 |
Vedaprofen or its salts or derivatives |
|
I |
DEC / 13 |
Vedolizumab |
|
I |
MAR / 15 |
Vegetable tar |
except shampoos in concentrations of 5% or less |
III |
SEP / 98 |
Velaglucerase alfa |
|
I |
DEC / 13 |
Velpatasvir |
|
I |
AUG / 16 |
Vemurafenib or its salts or derivatives |
|
I |
DEC / 13 |
Venetoclax or its salts |
|
I |
NOV / 16 |
Venlafaxine or its salts |
|
I |
DEC / 13 |
Verapamil or its salts |
|
I |
DEC / 13 |
Veratrum album or its alkaloids or their salts |
For human use.
|
I |
DEC / 13 |
Veratrum viride or its alkaloids or their salts |
For human use
|
I |
DEC / 13 |
Vernakalant or its salts |
|
I |
APR / 17 |
Verteporfin or its salts or derivatives |
|
I |
DEC / 13 |
Vidarabine |
|
I |
DEC / 13 |
Vigabatrin or its salts or derivatives |
|
I |
DEC / 13 |
Vilanterol or its salts |
Including but not limited to Vilanterol trifenatate
|
I |
DEC / 13 |
Vilazodone or its salts |
|
I |
AUG / 15 |
Vinblastine or its salts |
|
I |
DEC / 13 |
Vincristine or its salts |
|
I |
DEC / 13 |
Vindesine or its salts |
|
I |
DEC / 13 |
Vinorelbine or its salts |
|
I |
DEC / 13 |
Viomycin or its salts or derivatives |
|
I |
DEC / 13 |
Virginiamycin or its salts or derivatives |
|
I |
DEC / 18 |
Vismodegib |
|
I |
DEC / 13 |
Vitamin A |
For human use - in oral dosage forms containing more than 10,000 International Units of Vitamin A per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 10,000 International Units of Vitamin A.
|
I |
DEC / 13 |
Vitamin B12 with Intrinsic Factor Concentrate |
|
I |
DEC / 13 |
Vitamin D |
For human use - in oral dosage form containing more than 1,000 International Units of Vitamin D per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 1,000 International Units of Vitamin D.
|
I |
DEC / 13 |
Vitamin K |
For human use - except Vitamin K1 or Vitamin K2 sold (a) for external use in humans; or (b) in an oral dosage form for use in humans if the maximum recommended daily dose is 0.120 mg or less.
|
I |
DEC / 13 |
Vitamins |
any parenterals not otherwise included in Schedule I |
II |
SEP / 98 |
Vitamins in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Vorapaxar or its salts |
|
I |
AUG / 16 |
Voretigene neparvovecPDL |
|
I |
DEC / 20 |
Voriconazole |
|
I |
DEC / 13 |
Vorinostat |
|
I |
DEC / 13 |
Vortioxetine or its salts |
including but not limited to vortioxetine hydrobromide
|
I |
DEC / 14 |
Voxilaprevir or its salts |
|
I |
SEP / 17 |
Xanthinol nicotinate |
|
I |
DEC / 13 |
Xylazine or its salts |
|
I |
DEC / 13 |
Xylometazoline and it salts |
in nasal preparations for pediatric use (0.05%) |
II |
SEP / 98 |
Xylometazoline and its salts |
in nasal preparations for adults (0.1%) |
U |
|
Xylose |
|
II |
SEP / 98 |
Yellow Fever vaccine |
|
I |
FEB / 02 |
Yohimbine or its salts |
|
I |
DEC / 13 |
Zafirlukast or its salts |
|
I |
DEC / 13 |
Zalcitabine or its salts |
|
I |
DEC / 13 |
Zaleplon or its salts or its derivatives |
|
I |
NOV / 18 |
Zanamivir or its salts or derivatives |
|
I |
DEC / 13 |
ZeranolC |
|
I |
SEP / 98 |
Zidovudine |
|
I |
DEC / 13 |
Zinc chloride in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Zinc sulfate in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Zipeprol and any salt thereofC |
|
I |
NOV / 20 |
Ziprasidone or its salts |
|
I |
DEC / 13 |
Zoledronic acid or its salts or derivatives |
|
I |
DEC / 13 |
Zolmitriptan or its salts |
|
I |
DEC / 13 |
Zolpidem and any salt thereofTS |
|
I |
JAN / 03 |
Zomepirac or its salts |
|
I |
DEC / 13 |
Zopiclone or its salts |
|
I |
DEC / 13 |
Zucapsaicin |
|
I |
DEC / 13 |
Zuclopenthixol or its salts or derivatives |
Including but not limited to zuclopenthixol decanoate, zuclopenthixol hydrochloride.
|
I |
DEC / 13 |
alpha1- proteinase inhibitor (human) |
|
I |
JAN / 06 |